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INTRODUCTION: 
                    Type 2 diabetes mellitus (T2DM) is a chronic disease that is 
associated with obesity and the progressive development of hyperglycemia. 
Increased body fat is associated with the development of insulin resistance in 
muscle and in the liver, particularly if excess fat is deposited in these tissues . 
Initially, the pancreas is able to overcome this insulin resistance by producing more 
insulin, but in diabetes there is a progressive failure of β-cell output, resulting first 
in glucose intolerance and then overt T2DM. In addition to these established 
factors, it is now known that multiple defects, involving numerous metabolic 
pathways and organ systems, contribute to the progression of hyperglycemia in 
T2DM. It  include adipocytes (accelerated lipolysis), the gastrointestinal tract 
(incretin deficiency/resistance), pancreatic α-cells (hyperglucagonemia), the brain 
(insulin resistance), and the kidneys (increased glucose reabsorption).1 
                   Diabetes is a worldwide growing public health problem with high risks 
of severe micro vascular and macrovascular complications. Diabetic nephropathy 
(DN) is a major burden among the chronic complications of diabetes, given that it 
affects the 30% of patients with diabetes. Indeed, DN is the most common cause of 
end-stage renal disease . Known risk factors for DN include hyperglycemia, 
hypertension, dyslipidemia, smoking, and obesity as well as ethnic, familial, and 
genetic predispositions. Thus, large intervention trials on the impact of long-term 
intensified glucose control on chronic diabetes complications, both in type 1 and 
type 2 diabetes, have documented the critical role of glycemic control in 
preventing the development of early DN as well as in slowing its progression; In 
contrast, the clinical trials with renin-angiotensin-aldosterone system (RAAS) 
blockade versus other antihypertensive agents in primary prevention of DN have 
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provided conflicting results , when albuminuria is the primary outcome, by the 
rapid but reversible decreases in urinary albumin excretion rate and by the 
differences in blood pressure control. 
                    Among the most recent glucose-lowering oral agents, the sodium–
glucose cotransporter (SGLT) 2 inhibitors have the potential to exert  nephro 
protection through improving glycemic control but also through glucose-
independent effects, such as blood pressure–lowering and, possibly, some direct 
renal effects. Interestingly, SGLT2 inhibitors also have renal hemodynamic effects, 
including reducing glomerular hyperfiltration, as well as inhibitory effects on the 
inflammatory and fibrotic responses of proximal tubular cells to hyperglycemia. 
The SGLT2 is localized to the proximal tubule and is responsible for 90% of the 
reabsorption of the glucose filtered by the kidney. In type 2 diabetes, as a 
consequence of the increased glucose filtered load, there is an increased expression 
of SGLT2 and an increased reabsorption of glucose; this a maladaptive mechanism 
contributing to hyperglycemia . SGLT2 inhibition leads to substantial glycosuria 
and reduction in fasting and postprandial plasma glucose levels, without 
stimulating insulin secretion, and therefore without increasing the risk of 
hypoglycemia.2 
                   Diabetes was firmly established as an endocrine disease, and the 
potential role of the kidney in the pathogenesis of diabetes was largely ignored. 
Interestingly, attention is once again focused on the kidney, not only as an organ 
that may be adversely affected by diabetes, but also as an important player in 
glucose homeostasis and a potential target for the treatment of hyperglycemia in 
type 2 diabetes.  
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SUBJECTIVE INTRODUCTION: 
                  The kidney has historically been ignored as a potential target organ for 
the pharmacologic mitigation of hyperglycemia, as it was primarily considered an 
organ of elimination and a regulator of salt and ion balance. The kidney was once 
mistakenly thought to be the structural cause of diabetes, and in later years has 
essentially been ignored as a regulator of glucose homeostasis. Today, however, it 
is now recognized as an important contributor to glucose regulation. In line with 
this, we now have a clearer understanding of the physiology of glucose transport 
via specific carriers such as the sodium-glucose co-transporters (sodium-glucose 
linked transporters), or SGLTs.3 
                 The kidneys are crucial for maintaining glucose homeostasis, and 
contribute to this process via glucose uptake, gluconeogenesis, and reabsorption of 
glucose from the glomerular ﬁltrate into the circulation. On average, an 
individual’s entire blood volume is ﬁltered by the kidney more than 50 times daily, 
with around 160–180 g of glucose ﬁltered from plasma by glomeruli every day 
(180 L per day at approximately 100 mg/dL of glucose). Under normal 
circumstances, this ﬁltered glucose is almost completely reabsorbed in the 
proximal tubules of the kidney, leaving the urine free of glucose.                      
The reabsorption of ﬁltered glucose is mediated by SGLTs, a family of active, 
sodium-dependent, large trans-membrane proteins. Two members of the SGLT 
family are involved in glucose reabsorption in the kidney: SGLT2 is a high-
capacity, low affinity transporter, expressed in the early convoluted segment of the 
proximal tubule, and has traditionally been thought to be responsible for nearly 
90% of the active renal glucose re-absorption; while SGLT1, a high-afﬁnity, low-
capacity transporter, expressed in the distal segment of the proximal tubule, 
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reabsorbs the remaining 10%.SGLT2 is thought to be expressed exclusively in 
renal proximal tubules, but SGLT1 is also found in the gastrointestinal tract, where 
it is responsible for absorption of galactose as well as glucose.For both SGLTs, 
glucose reabsorbed from the proximal tubules by SGLTs is then passively diffused 
into the circulation via facilitative glucose transporters (GLUTs) at the basolateral 
membrane of the cells lining the proximal tubule. Glucose reabsorption in people 
with type 2 diabetes. 
                     In patients with type 2 diabetes, blood glucose levels eventually 
become so high that they exceed the capacity of the SGLT2 transporters, at a 
threshold of approximately 200 mg/dL (11.0mmol/L). Thus, not all glucose is 
reabsorbed, and glucose begins to appear in the urine. Unfortunately, in patients 
with ongoing hyperglycemia, up-regulation of glucose transporter genes increases 
the level of renal glucose reabsorption. This increased threshold for glucose 
transport minimizes UGE and intensiﬁes hyperglycemia; however, once this 
increased threshold is exceeded, the characteristic glucosuria is detected.4 
                    In recent years, realistic options for promoting UGE via SGLT 
inhibition have been identiﬁed. Efforts have focused on selective SGLT2 
inhibition, as this transporter is expressed almost exclusively in renal proximal 
tubules and its inhibition is therefore unlikely to affect other organ systems. 
Individuals who lack functional SGLT1 have severe gastrointestinal symptoms due 
to malabsorption of glucose and galactose, while people who lack a functional 
gene for SGLT2 generally lead normal healthy lives, despite the presence of 
higher-than-normal levels of glucose in their urine. In people lacking SGLT2 (a 
condition known as familial renal glycosuria), essential levels of glucose are 
maintained, and although SGLT2 normally transports around 90% of the 180 g of 
glucose reabsorbed, inhibition of SGLT2. 
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FIGURE 1: SODIUM GLUCOSE CO TRANSPORTER 2 INHIBITORS: AN 
EMERGING NEW CLASS OF  ORAL ANTIDIABETIC DRUG 
 
                 Typically only results in maximum excretion of about 50% (90 g) of 
glucose, suggesting that when SGLT2 is inhibited, SGLT1 capacity can be 
increased. Besides reduction in blood glucose, SGLT2 inhibition has the additional 
potential advantages of weight loss (corresponding to the calories lost daily in 
excreted glucose) as well as no increase in hypoglycemia (since insulin secretion is 
not stimulated) when used as monotherapy. Phlorizin, a compound originally 
isolated from the bark of apple trees, was the ﬁrst SGLT inhibitor identiﬁed. 
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Despite its ability to induce glucosuria, phlorizin was not clinically developed 
because it had low bioavailability, degraded rapidly after oral administration to 
phloretin (a potent inhibitor of GLUT transporters), and inhibited SGLT1 In the 
early proximal tubule,90% of glucose filltered is reabsorbed by SGLT2,unless 
SGLT2 is inhibited.5 
                  In the late proximal tubule,10% of glucose filltered is reabsorbed by 
SGLT1 Inhibition of SGLT2 significantly reduces filtered glucose being 
reabsorbed, and excess glucose is secreted into the urine In the small intestine, 
glucose is transported to the blood stream by SGLT1 cause Glucose Reduction in 
blood glucose level. 
GLUCOSE HOMEOSTASIS AND THE KIDNEY: 
                  Glucose regulation can be divided into three main processes: 1) glucose 
absorption, 2) glucose synthesis or production, and 3) glucose utilization. 
                   Endogenous glucose production occurs primarily in the liver, with 
hepatic glycogenolysis and gluconeogenesis accounting for 85% of endogenous 
production. However, it is important to note that gluconeogenesis is responsible for 
about 55% of glucose released during the non-fed period and thus has a significant 
impact on glycemia. The kidney warrants consideration in the overall picture of 
endogenous glucose synthesis because renal glucose production accounts for about 
20% of all overall endogenous glucose release and is also responsible for 
approximately 40% of glucose released secondary to gluconeogenesis. Therefore, 
the kidney plays an important role in glucose production. 
                   After glucose is ingested, an increase in plasma glucose concentration 
triggers insulin release, which in turn stimulates splanchnic and peripheral glucose 
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uptake and suppression of endogenous glucose production. Under normal 
circumstances in healthy individuals, blood glucose levels are tightly regulated 
within the range of 70 to 99 mg/dL and rarely exceed 140 mg/dL following 
postprandial consumption. These narrow ranges are maintained under a complex 
system that includes multiple hormones (e.g., insulin and glucagon), central and 
peripheral nervous system metabolic needs, and various cells and tissues (e.g., 
brain, muscle, GI tract, liver, kidney, and adipose tissue), which regulate the 
uptake, metabolism, storage, and excretion of glucose.6 
                  Two groups of glucose transporters mediate most cellular glucose 
transport: glucose transporters (GLUTs), which are expressed throughout the body, 
and SGLTs. The function of SGLTs will be discussed further below. 
                  Glucose utilization takes place primarily (over 80%) in the muscle. This 
glucose is utilized directly for energy or stored as glycogen. Under normal 
conditions, approximately 5% of peripheral glucose is taken up by fat tissue. The 
liver preferentially stores absorbed glucose in the form of glycogen when under the 
influence of insulin. 
                   With normal kidney function, 99% of filtered glucose is reabsorbed 
during periods of euglycemia. The glomerular filtration rate (GFR) and plasma 
glucose concentration govern the rate of glucose filtration. Under normal 
conditions, most if not all of the filtered glucose is reabsorbed. However, there is a 
maximum rate at which glucose can be reabsorbed (~375 mg/min in an average 
patient). The most salient SGLT in the kidney is SGLT2. SGLT2 accounts for 
approximately 90% of glucose reabsorption in the kidney and, because of this, has 
become the focus of this new category of medications, the SGLT2 inhibitors. 
SGLT2 transporters are found at a relatively high density on the brush-border 
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membrane of the S1 (early) segment of the proximal convoluted tubule. This 
transporter binds with both sodium ions (Na+) and glucose in the tubular filtrate. 
These compounds are then translocated across the cell membrane. Functionally, 
this process is driven by the electrochemical Na+ gradient between the tubular 
filtrate and the intracellular space and is called secondary active-transport. 
Glucose in the tubular epithelial cell is then transported down a concentration 
gradient across the basolateral membrane to the systemic circulation by GLUT1.7 
                        When the rate of glucose absorption exceeds 375 mg/min, glucose 
is excreted in the urine because its concentration has exceeded the ability of the 
SGLT2 transporters to reabsorb it. In most non diabetic persons, glucose 
concentrations will never be high enough to exceed the kidney’s ability to reabsorb 
the presented glucose. However, in patients with diabetes, glucosuria is common 
with blood glucose of 180 mg/dL or higher.SGLT2 inhibitors modulate this 
pathway by reducing the reabsorptive capacity of the renal tubules, with a resultant 
elimination of excess glucose.   
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 FIGURE 2: GLUCOSE REABSORPTION FROM THE GLOMERULAR 
FILTERATE THROUGH A PROXIMAL TUBULE EPITHELIAL CELL 
INTO BLOOD. 
Thus, the mechanism of action of the SGLT2 inhibitors is to simply inhibit the 
transporter, which in turn reduces the reabsorption of filtered glucose and lowers 
the renal threshold for glucose. The two main sodium–glucose co transporters 
(SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce 
hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to 
absorb glucose and contributes to the reabsorption of glucose filtered by the 
kidney.                     
                             SGLT2 is responsible for reabsorption of most of the glucose 
filtered by the kidney. Inhibitors with varying specificities for these transporters 
(eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal 
glucose absorption and increase the renal elimination of glucose into the urine. 
Results of randomised clinical trials have shown the blood glucose-lowering 
efficacy of SGLT inhibitors in type 2 diabetes when administered as mono therapy 
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or in addition to other glucose-lowering therapies including insulin. Increased renal 
glucose elimination also assists weight loss and could help to reduce blood 
pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and 
might increase risk of urinary tract and genital infection, and excessive inhibition 
of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent 
mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering 
efficacy with low risk of clinically significant hypoglycaemia at any stage in the 
natural history of type 2 diabetes. SGLT inhibition might also be considered in 
conjunction with insulin therapy in type 1 diabetes. 
                    The kidney plays a central role in the regulation of plasma glucose 
levels.The sodium glucose co-transporter type 2 (SGLT2) located in the plasma 
membrane of cells lining the proximal tubule mediates the majority of renal 
glucose reabsorption from the tubular fluid, which normally prevents the loss of 
glucose in the urine. Competitive inhibitors of SGLT2 that provoke the renal 
excretion of glucose have been discovered, thereby providing a unique mechanism 
to potentially lower the elevated blood glucose levels  in patients with diabetes.8 
                    The kidney contributes to the maintenance of blood glucose levels 
primarily by the reabsorption of glucose from the glomerular filtrate to the blood. 
Under normal conditions, almost all of the filtered glucose is reabsorbed and 
returned to the circulation in the proximal tubule of the nephron. Glucose is 
reabsorbed by sodium-glucose co transporters (SGLTs) in concert with facilitative 
glucose transporters (GLUTs).  
                    The ability of the kidneys to reabsorb glucose is limited by the 
capacity of these transporters, and as plasma concentrations exceed ~ 180–200 
mg/dl (the renal threshold), glucose starts to appear in the urine. Kidneys continue 
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to reabsorb glucose even in the presence of abnormally high plasma glucose 
concentrations 
                    The kidney plays a major role in glucose homeostasis because of its 
role in gluconeogenesis and the glomerular filtration and reabsorption of glucose in 
the proximal convoluted tubules. Approximately 180 g of glucose is filtered daily 
in the glomeruli of a normal healthy adult. Typically, all of this glucose is 
reabsorbed with <1% being excreted in the urine. The transport of glucose from the 
tubule into the tubular epithelial cells is accomplished by sodium-glucose co-
transporters (SGLTs). SGLTs encompass a family of membrane proteins that are 
responsible for the transport of glucose, amino acids, vitamins, ions and osmolytes 
across the brush-border membrane of proximal renal tubules as well as the 
intestinal epithelium. SGLT2 is a high-capacity, low-affinity transporter expressed 
chiefly in the kidney. It accounts for approximately 90% of glucose reabsorption in 
the kidney and has thus become the focus of a great deal of interest in the field of 
diabetes mellitus.9 
  RENAL GLUCONEOGENESIS IN THE POSTABSORPTIVE STATE: 
                  In the fasting state in healthy individuals, the kidneys contribute about 
20% to 25% of the glucose released into the circulation via gluconeogenesis (15–
55 g per day), with the liver responsible for the remainder via both glycogenolysis 
and gluconeogenes and Renal gluconeogenesis occurs predominantly within 
proximal tubule cells in the renal cortex, and is chiefly regulated by insulin and 
catecholamines (eg, adrenaline). Insulin reduces renal gluconeogenesis directly, 
and also reduces the availability of gluconeogenic substrates, such as lactate, 
glutamine, and glycerol, thus reducing glucose release into the circulation. 
Adrenaline stimulates renal gluconeogenesis and, stimulates renal glucose release,  
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inhibits insulin secretion, increases the supply of gluconeogenic substrates, and 
reduces renal glucose uptake. 
                   In patients with T2DM, both renal and hepatic glucose release are 
increased as a result of increased gluconeogenesis. The relative increase in renal 
gluconeogenesis is thought to be substantially greater than in hepatic 
gluconeogenesis (300% vs 30%). Renal glycogenolysis is minimal in healthy 
individuals but may play a role in increased renal glucose release in patients with 
T2DM, due to accumulation of glycogen in diabetic kidneys.10 
RENAL GLUCOSE RELEASE IN THE POSTPRANDIAL STATE: 
                    Renal gluconeogenesis increases during the postprandial state relative 
to the post absorptive state. Studies using stable isotopes to estimate renal glucose 
balance have shown renal glucose release increases more than 2-fold during the 
4.5-hour postprandial period. It is thought that this increase in renal glucose release 
allows for repletion of hepatic glycogen stores by permitting suppression of hepatic 
glucose release. The mechanisms for this are not known, but may include the 
postprandial increases in lactate and amino acids that are precursors for 
gluconeogenesis, as well as an increase in sympathetic nervous system activity. 
Indeed, renal glucose production accounts for  60% of endogenous glucose release 
during the postprandial period (4–6 hours after meals). 
                   The increase in glucose release over the 4.5-hour postprandial period 
has been shown to be roughly 30% higher (100 g vs 70 g) in patients with T2DM 
compared with healthy individuals, primarily due to increased endogenous glucose 
release. It is estimated that 40% of the increase in endogenous glucose release 
occurs via the kidney. Renal glucose release is regulated by insulin; thus, as insulin 
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resistance increases, suppression of renal glucose release decreases, increase in 
renal glucose reabsorption due to upregulation of renal glucose transporters 
(GLUTs).11 
 RENAL GLUCOSE TRANSPORT: 
                      The kidneys play a key role in glucose conservation, filtering 160 to 
180 g of glucose per day in healthy individuals, which is all reabsorbed within the 
proximal tubules and Glucose reabsorption occurs via both sodium glucose co-
transporters (SGLTs) and GLUTs. The energy for SGLT-mediated active transport 
of glucose across the cell membrane is derived from the sodium electrochemical 
potential gradient. This is maintained by the transport of intracellular sodium ions 
into the blood via sodium-potassium adenosine triphosphatase (ATPase) pumps 
situated in the basolateral membrane. GLUTs bind glucose, inducing a 
conformational change, and glucose is passively transported across the cell 
membrane from the intracellular compartment into the plasma.12        
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 FIGURE 3: EARLY PORTION OF THE PROXIMAL TUBULE AND 
DISTAL PROXIMAL TUBLE. 
                   Within the proximal renal tubule, 2 key subtypes of SGLT and GLUT 
are responsible for glucose reabsorption and are expressed at the luminal brush 
border and the basolateral membrane of the epithelial cells, respectively. 
                      SGLT2 is a high-capacity, low-affinity co-transporter that is 
responsible for the majority of renal glucose reabsorption, coupling the active 
transport of sodium and glucose in a 1:1 ratio within the early proximal tubule. 
Glucose is then reabsorbed into the circulation via GLUT2. Any remaining glucose 
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is reabsorbed by SGLT1, a high-affinity transporter expressed within the distal 
proximal tubule (sodium : glucose ratio of 2:1) and then reabsorbed into the blood 
via GLUT1. 
 RENAL GLUCOSE REABSORPTION AND THE RENAL THRESHOLD 
FOR GLUCOSE EXCRETION: 
                   The physiologic relationship between plasma glucose concentration 
and renal glucose flux (i.e., filtration, reabsorption, and excretion) has typically 
been described as a threshold-type relationship .The amount of glucose filtered by 
the kidneys increases in a linear manner with increasing plasma glucose 
concentration and decreases with declining glomerular filtration rate (GFR); renal 
glucose reabsorption increases linearly until a certain concentration of plasma 
glucose is present. However, there is a distinct deviation  from this linear 
relationship as the renal capacity to reabsorb glucose nears saturation that is 
thought to be due to variability in the maximal reabsorptive capacity between 
individual nephrons.13   
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FIGURE 4: TMG, TUBULAR MAXIMUM GLUCOSE 
REABSORPTIVE CAPACITY; RTG, RENAL THRESHOLD FOR 
GLUCOSE EXCRETION. 
                   Under normal conditions in healthy individuals, nearly all filtered 
glucose is reabsorbed in the renal tubules. However, when the filtered glucose load 
exceeds the tubular maximum glucose reabsorptive capacity excess glucose is 
excreted in the urine .The renal threshold for glucose excretion (RTG) is the plasma 
glucose concentration at which TmG is exceeded; below this concentration, 
glucosuria is minimal. whereas, in patients with T2DM, RTG is elevated. While 
studies evaluating RTG in patients with T2DM suggest some inter individual 
variability, many patients demonstrate elevated values above the normal range, 
with values ranging from 112 to 240 mg/dL (6.2–13.3 mmol/L). 
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FIGURE 5: LINEAR RELATIONSHIP BETWEEN UGE AND PLASMA 
GLUCOSE CONCENTRATION IN HEALTHY INDIVIDUALS AND 
PATIENTS WITH T2DM. 
                  TmG may also be elevated in individuals with diabetes, contributing to 
the worsening of hyperglycemia. Increased tubular reabsorption may be due to an 
increase in GLUT expression or activity, with up regulation of SGLT2 or GLUT2 
being possible mechanisms for the increase in glucose reabsorption.. In a 
hyperglycemic culture environment, both SGLT2 and GLUT2 mRNA levels and 
glucose transport were significantly higher in the T2DM group versus controls. 
The increases in tubular reabsorption in individuals with T2DM lead to an increase 
in glucose flux into the blood, resulting in an exacerbation of hyperglycemia. 
Based on observations that mean RTG is approximately 40 mg/dL (2.2 mmol/L) 
higher in patients with T2DM than the commonly reported values of 180 to 
200 mg/dL (10–11 mmol/L) in healthy individuals and using a mean GFR of 
100 mL/min, calculations suggest that elevated RTG leads to an average of 
approximately 50 to 70 mg/min of additional glucose reabsorbed into the 
circulation when plasma glucose is above the RTG, relative to glucose reabsorption 
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if RTG was not increased. For comparison, elevated hepatic glucose production is 
estimated to contribute approximately 24 mg/min of additional glucose in a 100-kg 
patient with T2DM. Thus, both the kidney and the liver substantially contribute to 
the hyperglycemia seen in patients with T2DM. However, it should be noted that 
additional renal glucose reabsorption may be substantially lower in patients with 
impaired renal function, since their GFR will be lower than 100 mL/min.14 
 GENETIC DEFECTS IN RENAL GLUCOSE TRANSPORT: 
                      Specific mutations in SGLT genes can result in naturally occurring 
glucosuria. Glucose-galactose malabsorption (GGM) is a rare condition caused by 
mutations of SGLT1, leading to malabsorption of these sugars due to failure of the 
gastrointestinal epithelial cells to accumulate sugar across the brush border 
membrane. This results in gastrointestinal symptoms such as diarrhea and 
dehydration presenting in the neonatal period; treatment requires removal of 
glucose and galactose (which is also transported by SGLT1) from the diet. 
Glucosuria in individuals with GGM is typically absent or mild, consistent with the 
minor role of SGLT1 in renal glucose reabsorption. 
                      Familial renal glucosuria (FRG) is a rare autosomal recessive renal 
disorder that results from mutations in the SLC5A2 gene (coding for SGLT2) in the 
majority of cases. Heterozygous FRG is characterized by glucosuria of ~ 0 to 
10 g/day at normal plasma glucose concentrations in the absence of renal tubular 
dysfunction. FRG is generally asymptomatic and considered to be a benign 
condition. Homozygous FRG may result in glucosuria of up to 200 g/day, but is 
rarely described.  
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SGLT2 INHIBITION IN T1DM: 
                   SGLT2 inhibition was associated with improvements in glycemic 
control, reductions in daily insulin doses, and reductions in body weight.  
 SGLT2 inhibition for the treatment of T2DM: 
                   Inhibition of SGLT2 has emerged as a focus for the development of 
novel treatments for patients with T2DM. These therapies reduce blood glucose 
concentrations by lowering the RTG and inducing glucosuria in an insulin-
independent manner. Two SGLT2 inhibitors, canagliflozin and dapagliflozin, are 
currently approved for use in patients with T2DM in over 30 countries worldwide. 
                   The importance of the kidney in glucose homeostasis has been 
recognized for many years. Recent observations indicating a greater role of renal 
glucose metabolism in various physiologic and pathologic conditions have 
rekindled the interest in renal glucose handling as a potential target for the 
treatment of diabetes. The enormous capacity of the proximal tubular cells to 
reabsorb the filtered glucose load entirely, utilizing the sodium-glucose co-
transporter system (primarily SGLT-2), became the focus of attention.  In general, 
a 6-month period of therapy with SGLT-2 inhibitors is followed by a mean urinary 
glucose excretion rate of ~80 g/day accompanied by a decline in fasting and 
postprandial glucose with average decreases in HgA1C ~1.0%. Concomitant body 
weight loss and drop in blood pressure also have been reported. In contrast, 
transient polyuria, thirst with dehydration and occasional hypotension have been 
described early in the treatment. In addition, a significant increase in the 
occurrence of uro-genital infections, particularly in women has been documented 
with the use of SGLT-2 inhibitors.16 
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                    Interestingly, attention is once again focused on the kidney, not only 
as an organ that may be adversely affected by diabetes, but also as an important 
player in glucose homeostasis and a potential target for the treatment of 
hyperglycemia in type 2 diabetes. the role of the kidney in normal glucose 
homeostasis and in type 2 diabetes and how inhibition of renal glucose 
reabsorption may become a novel treatment option in patients with type 2 diabetes. 
                    Type 2 diabetes is a progressive disease. As such, patients with type 2 
diabetes can have various levels of hyperglycemia, and therapy should be 
individualized, taking into account the duration of disease, life expectancy, 
presence of complications and comorbidities, and risk for severe hypoglycemia. 
For example, patients with an A1C ≤ 7.5% may be able to reach glycemic goals 
with monotherapy. In contrast, patients with an A1C of 7.6–9.0% will likely 
require two diabetes medications, and patients with an A1C > 9% will probably 
require two diabetes medications and insulin.  
                      SGLT2 inhibitors block the reabsorption of filtered glucose leading 
to glucosuria.  the glucosuria associated with SGLT2 inhibition is associated with 
caloric loss, thus providing a potential benefit of weight loss.SGLT2 inhibition  
cause glucose elevation in the urine lead to urinary tract and genital infections, 
electrolyte imbalances and increased urinary frequency.17 
SGLT2 INHIBITORS AND GLOMERULAR HYPERFILTRATION: 
                    The two most important pathophysiological mechanisms leading to 
renal hyperfiltration in diabetes are glomerular hemodynamic abnormalities due to 
neurohormonal activation and tubular factors. The hemodynamic/neurohormonal 
hypothesis is based on changes in afferent and efferent arteriolar tone, resulting in 
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glomerular hyperfiltration, mostly due to RAAS activation. The tubular hypothesis 
is based on the fact that hyperglycemia causes an increase in proximal tubule 
glucose filtered load in diabetes. This results in over activity of SGLT2 and 
SGLT1 and consequent increased tubular reabsorption of glucose and sodium and 
downstream activation of the tubuloglomerular feedback system . This increased 
proximal sodium reabsorption leads to decreased sodium delivery to and transport 
in the cells of the macula densa, with consequent reduction in ATP breakdown and 
adenosine production. Adenosine is a strong vasoconstrictor, and its reduction 
causes vasodilation of the afferent arteriole and thus hyperfiltration 
 
 
           
 
         FIGURE 6:TUBULOGLOMERULAR FEEDBACK SYSTEM  
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                  SGLT-2 is primarily expressed in the kidney on the epithelial cells 
lining the first segment of the proximal convoluted tubule. It is the major transport 
protein that promotes reabsorption from the glomerular filtration glucose back into 
circulation and is responsible for approximately 90% of the kidney's glucose 
reabsorption.  
                    By inhibiting SGLT-2, medications of the gliflozin class prevent the 
kidneys' reuptake of glucose from the glomerular filtrate and subsequently lower 
the glucose level in the blood and promote the excretion of glucose in the urine 
(glucosuria).  
                     Interestingly, attention is once again focused on the kidney, not only 
as an organ that may be adversely affected by diabetes, but also as an important 
player in glucose homeostasis and a potential target for the treatment of 
hyperglycemia in type 2 diabetes.18  
                       SGLT2 expression was localized to the brush border of the early 
proximal tubule in the human kidney and was found upregulated in genetic murine 
models of type 1 and 2 diabetes. SGLT2 may functionally interact with the Na/H 
exchanger NHE3 in the proximal tubule. SGLT1-mediated reabsorption explains 
the fractional renal glucose reabsorption of 40-50% during SGLT2 inhibition. 
SGLT2 is expressed on pancreatic alfa cells where its inhibition induces glucagon 
secretion. SGLT2 inhibition lowers glomerular filtration rate in hyperfiltering 
diabetic patients consistent with the tubular hypothesis of diabetic hyperfiltration. 
New data indicate a potential of SGLT2 inhibition for renal medullary hypoxia and 
ketoacidosis, but also for blood glucose effect-dependent and independent 
nephroprotective actions, renal gluconeogenesis inhibition, reduction in 
cardiovascular mortality, and cancer therapy. 
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                    Because of its role in glucose homeostasis, the kidney has become a 
target of drug therapy for the treatment of type 2 diabetes. Increasing the excretion 
of glucose by inhibition of SGLT2, the transporter responsible for the majority of 
glucose reabsorption, improves glycemic control in patients with type 2 diabetes. 
                In human tubular epithelial cells grown from urines of patients with type 
2 diabetes , there is an increase in the expression and glucose-transport capacity of 
SGLT2 compared with those from control subjects without diabetes. Thus, SGLT2 
inhibition should result in an increased delivery of sodium to the macula densa, a 
consequent increase in adenosine release, resulting in vasoconstriction of the 
afferent arteriole leading to a reduction in renal plasma flow and GFR.  
FIGURE 7: SODIUM GLUCOSE CO TRANSPORTER 2 INHIBITORS: AN 
EMERGING NEW CLASS OF  ORAL ANTIDIABETIC DRUG. 
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                         The most important structural changes in type 1 diabetes occur in 
the glomeruli, with thickening of the glomerular basement membrane, mesangial 
expansion, and podocyte injury; in the presence of more advanced DN, however, 
there are also important changes in the tubules and interstitium with tubular 
atrophy and interstitial fibrosis and inflammation . In contrast, among patients with 
type 2 diabetes and microalbuminuria or macroalbuminuria and preserved renal 
function , a substantial proportion (∼40%) has advanced tubulo-interstitial lesions 
despite only very mild glomerular lesions. These lesions include thickening and 
reduplication of tubular basement membrane, tubular atrophy, interstitial fibrosis, 
and chronic inflammation. When proximal tubular cells are grown in high-glucose 
conditions, there is an increased secretion of inflammatory molecules and 
profibrotic cytokines . In vivo, this leads to activation of inflammatory pathways, 
recruitment of macrophages, and further tubular damage and interstitial fibrosis. 
transforming growth factor-β probably plays a key role, promoting fibrosis and 
epithelial-to-mesenchymal transformation . The increase in glucose trafficking 
through the proximal tubular cells, an increased transport of glucose by SGLT2, 
could promote inflammation and fibrosis. Thus, it is tempting to hypothesize that 
in patients with type 2 diabetes and tubulointerstitial lesions SGLT2 inhibitors 
might be particularly useful in reducing tubulointerstitial fibrosis and 
inflammation.19 
SGLT2 INHIBITORS AND RENAL FUNCTION IN CLINICAL STUDIES: 
                   The changes in GFR during SGLT2 inhibition are similar in patients 
with normal renal function and in those with CKD. The time course of changes in 
renal function is typically characterized by a rapid decline in GFR during the first 
weeks of treatment, followed by a progressive recovery that is faster and more 
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evident in patients with normal renal function at baseline. In addition to the effects 
on GFR, SGLT2 inhibitors also influence albuminuria.  Additional recent data also 
support the concept that SGLT2 inhibitors reduce albuminuria.  
                  By inhibiting SGLT-2, medications of the gliflozin class prevent the 
kidneys' reuptake of glucose from the glomerular filtrate and subsequently lower 
the glucose level in the blood and promote the excretion of glucose in the urine. 
                     Interestingly, attention is once again focused on the kidney, not only 
as an organ that may be adversely affected by diabetes, but also as an important 
player in glucose homeostasis and a potential target for the treatment of 
hyperglycemia in type 2 diabetes.  
                      SGLT2 expression was localized to the brush border of the early 
proximal tubule in the human kidney and was found up regulated in genetic  
murine  models of type 1 and 2 diabetes. SGLT2 may functionally interact with the 
Na/H exchanger NHE3 in the proximal tubule. SGLT1-mediated reabsorption 
explains the fractional renal glucose reabsorption of 40-50% during SGLT2 
inhibition. SGLT2 is expressed on pancreatic alfa cells where its inhibition induces 
glucagon secretion. SGLT2 inhibition lowers glomerular filtration rate in 
hyperfiltering diabetic patients .New data indicate a potential of SGLT2 inhibition 
for renal medullary hypoxia and ketoacidosis, but also for blood glucose effect-
dependent and independent nephroprotective actions, renal gluconeogenesis 
inhibition, reduction in cardiovascular mortality, and cancer therapy.20 
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GLUCOSE-LOWERING EFFICACY OF SGLT2 INHIBITORS IN 
PATIENTS WITH CKD: 
The efficacy of SGLT2 inhibitors in reducing plasma glucose is expected to be 
decreased with decreasing renal function. Since glucose-lowering agents for 
patients with CKD stages 3 and 4 are limited and frequently require dose 
adjustments, the identification of the cut off of estimated GFR (eGFR) below 
which clinically significant reductions in plasma glucose cannot be achieved with 
SGLT2 inhibitors is crucial. On the basis of the studies performed so far in patients 
with CKD, these drugs should not be started in patients with eGFR <60 
mL/min/1.73 m2 and should be stopped when eGFR is <45 mL/min/1.73 m2. 
                The kidney is the organ that filters about 45 gallons of blood each day. 
Most of the glucose in this blood is reabsorbed by the kidneys by a protein called 
Sodium-Glucose co transporter-2 (SGLT2). Here SGLTs are responsible for 
mediating glucose reabsorption in the kidneys. The inhibition of Sodium-Glucose 
co transporter-2, the re-absorption of the glucose back in to systemic circulation is 
by passed and the unabsorbed glucose is excreted through urine.21 
                  The kidneys play an important role in regulating glucose homeostasis 
through gluconeogenesis, glucose uptake and utilization, and glucose reabsorption 
in the proximal renal tubule. The RTG is the plasma glucose concentration at which 
glucose reabsorption capacity is exceeded and glucosuria occurs. The RTG has 
been estimated to be between 180 and 200 mg/dL (10–11 mmol/L) in healthy 
individuals; this is increased in patients with T2DM. The resulting increase in 
glucose reabsorption is thought to contribute to the maintenance of hyperglycemia. 
Type 2 diabetes is a progressive disease. As such, patients with type 2 diabetes can 
have various levels of hyperglycemia, and therapy should be individualized, taking 
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into account the duration of disease, life expectancy, presence of complications and 
co-morbidities, and risk for severe hypoglycaemia. 
                 Because of its role in glucose homeostasis, the kidney has become a 
target of drug therapy for the treatment of type 2 diabetes. Increasing the excretion 
of glucose by inhibition of SGLT2, the transporter responsible for the majority of 
glucose reabsorption, improves glycemic control in patients with type 2 diabetes. 
                  In the kidney, glucose is freely filtered at the glomerulus and is 
reabsorbed via active transport mechanisms in the proximal convoluted tubule. 
Two sodium-glucose co-transporters are responsible for glucose reabsorption: 
SGLT1 and SGLT2. SGLT1, which is also found in the gut and other tissues, 
accounts for about 10% of reabsorption. SGLT2, expressed exclusively in the S1 
segment of the proximal tubule, accounts for about 90% of reabsorption The 
concentration gradient that drives the action of these transporters is driven by the 
Na+/ATPase pump and by transport back into the blood via the GLUT2 glucose 
transporter . This suggests that the most promising target for drug development is 
the SGLT2 transporter, both because it is responsible for most glucose 
reabsorption and because of its exclusive localization to the kidney.23 
                 Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of 
diabetic medications indicated only for the treatment of type 2 diabetes. In 
conjunction with exercise and a healthy diet, they can improve glycemic control. 
SGLT2 is a protein in humans that facilitates glucose reabsorption  in  the     
kidney. SGLT2 inhibitors block the reabsorption of glucose in the kidney, increase 
glucose excretion, and lower blood glucose levels.    
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   FIGURE 8: SGLT-2 IS PRIMARILY EXPRESSED IN THE KIDNEY 
SGLT-2 is primarily expressed in the kidney on the epithelial cells lining the first 
segment of the proximal convoluted tubule. It is the major transport protein that 
promotes reabsorption from the glomerular filtration glucose back into circulation 
and is responsible for approximately 90% of the kidney's glucose reabsorption.  
                       The mechanism of action of SGLT2 inhibitors is independent of 
insulin secretion or action and complementary to existing diabetes medications, 
they may be effective across all stages of the disease when used as monotherapy or 
in combination with metformin, sulfonylureas, thiazolidinediones, or insulin. 
Additional effects that have been reported in some trials of SGLT2 inhibitors 
include weight loss and blood pressure reduction, both of which are beneficial in 
this patient population. 
                    SGLTs are responsible for mediating glucose reabsorption in the 
kidneys, as well as in the gut and the heart. SGLT-2 is primarily expressed in the 
kidney on the epithelial cells lining the first segment of the proximal convoluted 
tubule. It is the major transport protein that promotes reabsorption from the 
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glomerular filtration glucose back into circulation and is responsible for 
approximately 90% of the kidney's glucose reabsorption. By inhibiting SGLT-2, 
medications of the gliflozin class prevent the kidneys' reuptake of glucose from the 
glomerular filtrate and subsequently lower the glucose level in the blood and 
promote the excretion of glucose in the urine (glucosuria).24  
                
                          
               FIGURE 9: GLUCOSE REABSORPTION IN THE KIDNEY 
                   Sodium and glucose are co-transported by the SGLT-2 protein into the 
tubular epithelial cells across the brush-border membrane of the proximal 
convoluted tubule. This happens because of the sodium gradient between the 
tubule and the cell and therefore provides a secondary active transport of glucose. 
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Glucose is later reabsorbed by passive transfer of endothelial cells into the 
interstitial glucose transporter protein.  
                 In humans, SGLT2 inhibition was recently shown to reduce 
hyperfiltration in normotensive, normoalbuminuric patients with type 1 diabetes. In 
clinical trials of type 2 diabetes, SGLT2 is associated with significant renal effects, 
including modest, acute declines in estimated glomerular filtration rate followed by 
the maintenance of stable renal function, and reduced albuminuria. 
                hyperfiltration has been used as a surrogate marker for increased 
intraglomerular pressure in patients with diabetes mellitus. Previous human 
investigation examining the pathogenesis of hyperfiltration has focused on the role 
of neurohormones such as the renin-angiotensin-aldosterone system (RAAS). 
Unfortunately, RAAS blockade does not completely attenuate hyperfiltration or 
diabetic kidney injury. More recent work has therefore investigated the 
contribution of renal tubular factors, including the sodium-glucose cotransporter, to 
the hyperfiltration state,  
                 Moreover, Gilbert highlights the initial drop in eGFR in the treatment 
group. In the following 100 weeks, eGFR slowly fell in the placebo group, while it 
stabilized and even rose slightly in the treatment group. He noted that the initial 
fall in eGFR in the treatment group could be related to mild volume depletion, 
while the longer-term results could suggest possible nephroprotective effects in 
SGLT2 inhibitors similar to that seen with ACE inhibitors.25 
                 Increasing the excretion of glucose by inhibiting SGLT2 has a number 
of potential benefits. SGLT2 inhibitors, by increasing the excretion of glucose, 
decrease plasma glucose concentrations and have the additional benefit of reducing 
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body weight. Moreover, because the mechanism of action of SGLT2 inhibitors 
does not depend on the presence of insulin, the efficacy of SGLT2 inhibitors would 
not be primarily affected by the magnitude of insulin resistance or impairment of 
pancreatic β-cell function that accompanies type 2 diabetes progression. In 
addition, the risk of major hypoglycemic events is low with SGLT2 inhibitors 
because they do not impair normal endogenous glucose production in response to 
hypoglycemia and do not stimulate insulin release, suggesting that SGLT2 
inhibitors may preserve the hypoglycemia counter regulatory response of 
glucagon-mediated glucose production. Finally, there is a potential for combination 
therapy with other diabetes agents, including insulin, to improve glycemic control.  
                   As discussed below, results from clinical trials have confirmed that 
SGLT2 inhibition improves glycemic control, reduces body weight, and is 
effective when used as monotherapy or as add-on therapy to commonly used 
diabetes medications in patients with type 2 diabetes, both in drug-naive patients 
with a short duration of disease and in those with a long history of type 2 diabetes 
who are receiving insulin therapy. However, because SGLT2 inhibitors depend on 
the filtration and delivery of glucose to the proximal tubule, they are not effective 
in patients with moderate to severe renal impairment. Furthermore, continual 
excretion of urine with high glucose concentrations may predispose individuals to 
genital and urinary tract infections. 
                  Sodium and glucose are co-transported by the SGLT-2 protein into the 
tubular epithelial cells across the brush-border membrane of the proximal 
convoluted tubule. because of the sodium gradient between the tubule and the cell 
and therefore provides a secondary active transport of glucose. Glucose is later 
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reabsorbed by passive transfer of endothelial cells into the interstitial glucose 
transporter protein.  
                     Since sodium glucose co transporter 2 (SGLT2) inhibitors rely on the 
glomerulus to filter urine, their ability to lower blood glucose is limited in patients 
with type 2 diabetes who have chronic kidney disease (CKD). On the other hand, 
there is some research to suggest that use of SGLT2 inhibitors may confer some 
degree of nephroprotection.SGLT2 inhibitors could slow the progression of 
diabetic nephropathy,  by decreasing glomerular hyper filtration, hyperglycemia-
related tubular growth, kidney hypertrophy, and inflammation and fibrosis 
implicated in the development of diabetic nephropathy.  
                    Nephro protective potential of SGLT2 inhibitors  suppress renal hyper 
filtration independent of their effect on blood glucose levels. Conversely, the 
ability of SGLT2 inhibitors to reduce kidney growth and injury seems to depend on 
their glycemia-lowering effects. Inflammatory and fibrotic responses resulting 
from high glucose levels could also be decreased by SGLT2 inhibition, likely by 
blocking glucose entry into the cell.26  
ADVANTAGES AND DISADVANTAGES OF USING SGLT2 INHIBITORS 
TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH T2D: 
ADVANTAGES: 
•Significant improvements in glycemic control sustained over time. 
•Sustained, clinically meaningful reductions in body weight. 
•Sustained, clinically meaningful reductions in systolic blood pressure. 
•Insulin-independent mechanism of action. 
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•Improvements in insulin sensitivity and β-cell function. 
•Generally safe and well tolerated. 
•Low risk of hypoglycemia. 
•Can be used as mono therapy or combined with other AHAs, including    insulin. 
 
DISADVANTAGES: 
•Increased incidence of mild to moderate genital mycotic infections and UTIs vs 
comparators. 
•Higher incidence of osmotic diuresis related  AEs vs comparators. 
•Increased incidence of volume depletion– related AEs in elderly patients and in 
patients with eGFR < 60 mL/min/1.73 m2 
•Increased LDL-C level.27 
                    As the prevalence of T2DM grows, selecting appropriate 
antihyperglycemic agents to manage T2DM will continue to challenge healthcare 
providers. Overall, it is likely that SGLT2 inhibitors will prove to be valuable new 
anti hyperglycemic agents for the treatment of patients with T2DM.  
                 Selective sodium-glucose transporter-2 (SGLT-2) inhibitors are a class 
of oral hypoglycemics used in patients with diabetes mellitus type 2. These agents 
lower the renal glucose threshold, resulting in an increased amount of glucose 
being excreted in the urine. 
                 SGLT2 inhibitors inhibit the SGLT2 in the proximal nephron, 
subsequently reducing the reabsorption of filtered glucose. Excretion of glucose in 
the urine is increased by up to 80g per day . These agents provide modest weight 
INTRODUCTION 
 
DEPARTMENT OF PHARMACY PRACTICE Page 34 
 
loss as the result of increased loss of urinary glucose and reduction in blood 
pressure by means of osmotic diuresis effects .An additional advantage of SGLT2 
inhibitors is that these agents are effective at all stages of type 2 diabetes mellitus 
(T2DM) . When therapy is advanced to combination basal/bolus insulin regimens, 
physicians may discontinue agents such as sulfonylureas and GLP-2 receptor 
agonists. SGLT inhibitors can be utilized as adjuantive therapy to improve glucose 
control and reduce the amount of insulin needed. 
                  All of the SGLT2 inhibitors are available as an oral tablet formulation. 
The oral bioavailability of the SGLT2 inhibitors range from 60-78% and achieves 
maximum concentration 1-2 hours after administration. The elimination half-life of 
this class of medication ranges from 10.2-13.1 hours and have a once-daily dosing. 
Drug metabolism is primarily through glucuronidation by the liver and excretion of 
the drug is mainly by means of the urinary and fecal route. Since the SGLT2 
inhibitors reduce the reabsorption of glucose in the kidney and reduce filtration 
rates, patients with renal impairment will require additional monitoring and/or dose 
adjustment. The risk of hypoglycemia is low when a SGLT2 inhibitor is 
administered as monotherapy. In combination therapy, the SGLT2 drug class may 
enhance the hypoglycemic effects with insulin and insulin secretagogues such as 
sulfonylureas. Prescribers should consider lowering the dose of insulin and 
monitoring for signs and symptoms of hypoglycemia when initiating SGLT2 
adjunctive therapy.28  
                   Genitourinary infections and polyuria were the most commonly 
reported adverse events and patients presenting with symptoms should be 
evaluated. Hypotension, dizziness, and dose-related increase in LDL cholesterol 
have also been reported. Fractures are rare, but have occurred in susceptible 
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patients. Due to the renal mechanism of action of SGLT2 inhibitors, clinicians 
need to assess renal function. As this class of medication is contraindicated in 
patients with severe renal function including eGFR <30mL/min/1.73m [2], end-
stage renal disease or on dialysis. Bladder cancer has been reported in patients 
treated with SGLT2 inhibitors in clinical trials, but there is insufficient data to 
determine if these cases were related to the effects of SGLT2 medications. Case 
reports of ketoacidosis have been identified in post-marketing surveillance, and the 
American Association of Clinical Endocrinologists (AACE) and American College 
of Endocrinology (ACE) have found in their review of these cases that the 
incidence of ketoacidosis to be infrequent. If ketoacidosis is suspected or if patient 
is at risk for ketoacidosis. the SGLT2 agent should be discontinued immediately.29 
MECHANISM OF ACTION: 
                      Functioning of SGLTs are dependent on the Na+/K+ ATPase pump 
on the baso-lateral membrane which uses ATP to move sodium ions outward into 
the blood, while bringing in potassium ions. This creates a downhill sodium ion 
gradient inside the cell in comparison to both the blood and the tubule/ gastric 
lumen. The SGLT proteins use the energy from this downhill sodium ion gradient 
created by the ATPase pump to transport glucose across the apical membrane 
against an uphill glucose gradient. Therefore, these co-transporters are an example 
of secondary active transport. Since both sodium ions and glucose are transported 
in the same direction across the membrane, they are also called symporters. 
                    Around 180 grams of glucose is filtered by the renal tubules per day. 
Virtually all of this is re-absorbed from the proximal tubules, and re-enters the 
circulation. 90% of this re-absorption is SGLT2 mediated and the remaining by 
SGLT1. Inhibition of these SGLT2 channels by SGLT2 inhibitors leads to 
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persistent increased glycosuria, and lowering of blood glucose which leads to 
decreased glucotoxicity, decreased insulin resistance, and an improvement in 
insulin secretion. The advantage of this group of drugs is that their action is 
independent of residual beta cell function. This means that SGLT2 inhibitors may 
find a place in the management of T1D as well. Interestingly, in a follow-up study, 
it has been demonstrated that use of SGLT2 inhibitor, LX4211 (300 mg) resulted 
in significantly increased GLP-1 & peptide YY levels, probably by delaying 
SGLT1-mediated intestinal glucose absorption. Hence SGLT2 inhibitors exhibit 
some incretin-based effects as well.21 
                       
 
                                             FIGURE 10:KIDNEY NEPHRON 
                    SGLTs are responsible for mediating glucose reabsorption in the 
kidneys, as well as in the gut and the heart. SGLT-2 is primarily expressed in the 
kidney on the epithelial cells lining the first segment of the proximal convoluted 
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tubule. It is the major transport protein that promotes reabsorption from the 
glomerular filtration glucose back into circulation and is responsible for 
approximately 90% of the kidney's glucose reabsorption. By inhibiting SGLT-2, 
medications of the gliflozin class prevent the kidneys' reuptake of glucose from the 
glomerular filtrate and subsequently lower the glucose level in the blood and 
promote the excretion of glucose in the urine. 
                     Sodium and glucose are co-transported by the SGLT-2 protein into 
the tubular epithelial cells across the brush-border membrane of the proximal 
convoluted tubule. This happens because of the sodium gradient between the 
tubule and the cell and therefore provides a secondary active transport of glucose. 
Glucose is later reabsorbed by passive transfer of endothelial cells into the 
interstitial glucose transporter protein.30 
PATHOPHYSIOLOGY OF TYPE 2 DIABETES:  
                    Type 2 diabetes is characterized by resistance to the glucose-lowering 
effects and some other effects of insulin and a progressive failure of pancreatic 
beta-cell function.. This can be seen with regard to the genetics of the condition; 
there is a high degree of heritability (about 70% concordance in identical twins), 
but it is likely that many genes contribute. Recent genome-wide association studies 
have identified TCF7L2, which may relate to insulin secretion, and FTO -- variants 
of which are associated with a slight increase in body fat as being potentially 
important. Rare single-gene defects result in maturity-onset diabetes of the young 
(MODY), which can manifest as a pancreatic defect (eg, with a defect in the 
pancreatic glucose sensor glucokinase, MODY 2) or in hepatic and pancreatic 
function (hepatocyte nuclear factor [HNF]-1 alpha and HNF-4 genes, MODY 3, 
and MODY 4). Some cases are associated with autoimmunity and may in fact be a 
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slow-onset form of type 1 diabetes (late-onset autoimmune diabetes [LADA]). 
Hence, it is unlikely that any single pathophysiologic mechanism will eventually 
explain all cases of type 2 diabetes or suggest a therapeutic advance that will be 
suitable for all patients with the condition.31 
THE ROLE OF THE KIDNEY IN NORMAL GLUCOSE HOMEOSTASIS: 
                    The kidney plays a vital role in the normal control of blood glucose, 
mainly because glucose in the blood is freely filtered by the glomerulus and has to 
be reabsorbed. The kidney also contributes to gluconeogenesis, and can make up to 
about 5% to 10% of overall glucose production in humans. In healthy individuals, 
the kidneys filter about 100 mg/minute of glucose; this amounts to 144 g/24 hours. 
Nearly 100% of this glucose is reabsorbed, mostly in the proximal renal tubules. At 
a threshold of about 8-10 mmol/L (180 mg/dL), the capacity to reabsorb glucose is 
exceeded and glucosuria develops in proportion to the level of blood glucose. This 
renal threshold for glucose there is some variation from the idealized curve and 
what is observed from actual measurements in humans. This "splay" is thought to 
occur as a result of the differences between the filtration rate of individual 
nephrons and the fact that the transport system, like all biological systems, is not 
100% perfect at reabsorbing all of the filtered glucose.  
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                            FIGURE 11: RENAL GLUCOSE FLUXES  
In normal glucose reabsorption threshold occurs at 8.3 mmol/L plasma glucose and 
is saturated at around 13.3 mmol/L. Glucose excretion then increases linearly. 
Splay is thought to represent a slight variation between thresholds of individual 
nephrons. 
Glucosuria thus occurs in the presence of hyperglycemia, and has been used to 
demonstrate the presence of diabetes and monitor glycemic control long before the 
routine measurement of capillary blood glucose became possible.32  
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MECHANISMS RESPONSIBLE FOR RENAL GLUCOSE 
REABSORPTION: 
                   Most glucose reabsorption occurs in the proximal tubules of the 
nephron, mainly in the S1 and S2 segments, with a small contribution from the S3 
segment. This occurs via active transport mechanisms. There are 12 facilitative 
glucose transporters (GLUT-1 to GLUT-12) that transport glucose and other sugars 
into cells and play vital roles in glucose metabolism, including transporting 
glucose into and out of cells. However, the primary transporters responsible for the 
renal reabsorption of glucose are the 2 sodium-dependent glucose transporters 
SGLT1 and SGLT2. The genes coding these transporters are from 6 members of 
the SLC5 gene family, of which 2 have been fully characterized; 4 others exist, but 
their role and functions are less completely defined.  
                   SGLT1 is a high-affinity, low-capacity glucose/galactose transporter 
found in the gut, brain, skeletal muscle, liver, lungs, and kidneys. It is the main 
sodium-dependent glucose transporter in the gastrointestinal tract, and is necessary 
for the normal absorption of dietary glucose. Low levels of expression are also 
found in the S3 segment of the proximal renal tubule, where it may contribute to 
the renal reabsorption of glucose; however, individuals with mutations in the 
SGLT1 gene exhibit severe glucose and galactose malabsorption but only mild 
glucosuria. SGLT1 couples absorption of 2 molecules of sodium with 1 of glucose 
at the intestinal brush border membrane. Transport into blood is mediated by 
GLUT-2, which is coupled to exchange of 3 molecules of sodium and 2 of 
potassium . SGLT2 is a low-affinity, high-capacity transporter that is expressed 
almost exclusively in the S1 and S2 segments of the renal proximal tubule, where it 
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is ideally placed as the main transporter responsible for renal glucose 
reabsorption.33 
 
FIGURE 12: MODE OF ACTION OF SGLT1 AND SGLT2. 
Both are dependent on Na/K pump to drive glucose transport. SGLT1 is a high-
affinity/low-capacity glucose/galactose transporter, whereas SGLT2 a low-
affinity/high-capacity glucose transporter. 
                   In patients with uncontrolled diabetes, glucosuria is almost invariably 
present, and it may occur transiently even in patients with well-controlled diabetes 
if the renal threshold is exceeded for any significant length of time. High levels of 
glucosuria may lead to symptoms of polyuria and thirst, due to the osmotic effect 
of glucose. It has been suggested that high levels of glucosuria may also contribute 
to the increased risk for genitourinary fungal infections (mostly candidiasis) seen 
in uncontrolled diabetes, and possibly to an increased risk for urinary bacterial 
sepsis. Glucosuria also results in loss of energy in the urine. In patients with a 
blood glucose 50% above the renal threshold, this could result in the loss of 144 g 
of glucose -- equivalent to nearly 600 kcal energy per day  in the urine. Indeed, it 
has been shown that a significant amount of the weight gain seen with improved 
glucose control with insulin therapy in type 2 diabetes is due to the abolition of 
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renal glucosuria; thus, paradoxically, glucosuria may be of possible benefit in 
patients with diabetes.34 
                     Perhaps the most compelling data in support of the concept that 
glucosuria in the absence of diabetes is not harmful come from the study of rare 
individuals with the condition familial renal glucosuria. These individuals have 
lifelong glucosuria at varying levels as a result of mutations in the SLGT2 gene. 
The reported mutations occur at varying sites in the gene, and affected individuals 
are usually homozygotes or compound heterozygotes for such mutations, although 
heterozygotes may have some glucosuria. Other than glucosuria, which is usually 
identified by chance through medical screening or as a result of family history, 
most people with these genetic abnormalities appear healthy and are reported to 
have a normal life span. Several different mutations have been described, with 
varying levels of glucosuria. One individual with over 60 g/day of glucosuria was 
reported to show salt-wasting, with evidence of natriuresis and activation of the 
renin-angiotensin system, but this does not appear to be a common feature of the 
syndrome. 
                   Renal glucose handling includes free glomerular filtration with 
complete proximal tubular reabsorption into the renal interstitial fluid space. Renal 
gluconeogenesis that takes place in the proximal tubular cells adds a small fraction 
to the glucose load that exchanges with the peri-tubular capillaries along the 
proximal nephron. In the distal nephron, glucose extracted can be either stored in 
the form of glycogen or oxidized to generate energy. In turn, no glucose is excreted 
in the urine and nearly all filtered glucose load perfusing the distal nephron is 
restored to the peripheral circulation, after mixing in the renal vein with the 
remainder 80% of unfiltered blood.35 
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                     The sodium-glucose co-transport system (SGLT) is located at the 
luminal membrane of the proximal renal tubular cells. These cells contain specific 
enzymes that enable glucose synthesis de novo [renal gluconeogenesis], although 
no enzymatic activity for concomitant glucose utilization, storage or oxidation has 
ever been identified in proximal tubules.  
                     Plasma glucose is freely filtered at the glomerulus and completely 
reabsorbed in the proximal tubules. The SGLT-2 transporters located at the luminal 
membrane of cells in the S1 and S2 segments are responsible for 90% of total 
glucose re-uptake. The SGLT-1 transporters located downstream in the S3 segment 
of the proximal tubules account for the remainder 10% of the glucose load 
reabsorbed into the renal interstitial fluid. The process of renal gluconeogenesis 
occurs exclusively in the proximal tubular cells, whereas glucose utilization is 
limited to the distal nephron. Glycogen synthesis and storage, as well as complete 
glucose oxidation are detected only in cells of the distal nephron and, partial 
oxidation (anaerobic glycolysis) with formation and release of lactate is a 
characteristic of the hypoxic medullary regions of the kidney.36 
                   In contrast, the distal nephron has sufficient biochemical capability to 
metabolize the glucose extracted from the peri-tubular fluid and, the renal medulla 
is in fact an obligatory site for glucose oxidation. Because most of the energy 
required by the mega-transport tubular activity is supplied primarily from the 
oxidation of fatty acids, glucose sparing by the kidney is enabled and represents a 
critical aspect in the maintenance of whole-body glucose homeostasis. 
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RENAL GLUCOSE TRANSPORT AND METABOLISM: 
                 Various glucose transmembrane transport systems and intracellular 
metabolic pathways have been well characterized in the kidney. Most information 
is derived from in vitro cell preparations and renal perfusion studies Glucose is 
actively transported from the lumen to the tubular cells essentially by two 
transmembrane proteins: one with high capacity-low affinity termed sodium-
glucose transport SGLT-2 and a second with high affinity-low capacity transporter 
termed SGLT-1. The SGLT-2 is found in the earlier S1 and S2 segments of the 
proximal tubule and the SGLT-1 in the S3 segment of the proximal tubules, which 
is also abundant in the enterocytes of the intestinal mucosa.37  
                  Considering that nearly 180 liters of plasma are filtered daily by the 
kidneys with plasma glucose concentrations ranging between 80-120 mg/dl (an 
average of 100 mg/dl), the glucose load that crosses the glomeruli is estimated to 
be around 180 grams per day. Circulating glucose is neither protein-bound nor 
attached to macromolecules and thus, is freely filtered at the glomerulus. The 
ultrafiltrate carries the glucose towards the luminal side of the early S1 segment in 
the proximal tubules, where SGLT-2 is located. The active process of re-uptake of 
glucose is coupled with the transport of sodium cations and the complex is 
transferred to the cell membrane at the level of the S1 segment.38 
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                              FIGURE 13:RENAL GLUCOSE UTILIZATION 
                   This same system is also utilized to carry amino acids from the lumen 
into the proximal tubular cells. The SGLT-2 transport activity across the luminal 
membrane is driven by an electro-chemical gradient, which is created by the action 
of the ATPase-mediated sodium-potassium pump located in the baso-lateral 
membrane of the cells. The energy consumed in this active transport process is 
supplied entirely from ATP derived the oxidation of intracellular fatty acids.11 As 
glucose builds up inside the proximal tubular cells, a facilitated passive transport in 
favor of a concentration gradient and mediated by GLUT-2 transporters, transfers 
intact glucose molecules out and into the surrounding renal interstitial fluid. In 
addition to restoring glucose to the interstitial fluid and eventually to the peripheral 
circulation, this sodium co-transport process also contributes to the maintenance of 
fluid and electrolyte balance by the kidney.39 
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                   In physiologic conditions the high capacity of the SGLT-2 co-transport 
system is responsible for the reabsorption of nearly 90% of all filtered glucose 
load. The re-uptake of the remainder 10% of the glucose load is a function of the 
low-capacity-high affinity SGLT-1 co-transporter and takes place downstream in 
the S3 segment of the proximal tubules.SGLT-1 represents a major mechanism via 
which glucose and galactose derived from the meals are absorbed in the intestines.  
                    On the other hand, the fact that SGLT-2 is exclusively found in the 
proximal tubules of the kidney, as opposed to SGLT-1 or GLUT-2, makes this 
transporter suitable for more specific renal pharmacologic interventions. Thus, the 
possibility of interfering with the activity of the SGLT-2 has become of 
considerable clinical significance. It should be emphasized that there is a minor 
contribution to the glucose load released into the interstitial fluid provided by the 
process of renal gluconeogenesis.  
                  This is possible because proximal tubular cells contain the enzymes 
necessary to synthesize glucose de novo, including glucose-6-phosphatase, the last 
step which enables newly-formed glucose to be de-phosphorylated and then 
secreted into the extra-cellular space. The fact that there is no detectable 
biochemical capacity in the proximal tubular cells to either utilize or store glucose, 
enables the entire filtered glucose load to be released unaffected into the renal 
interstitium. Thus, together with the small fraction of newly-synthesized glucose 
added by the proximal tubules the glucose-rich interstitial fluid exchanges with the 
renal venous capillaries and reaches the renal vein.40 
                   Unlike the proximal nephron, cells in the distal nephron are fully 
capable of glucose utilization. In physiologic conditions, the amount of glucose 
utilized in the distal segments of the nephron equals that derived from the renal 
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gluconeogenesis in proximal tubules. This is confirmed by the common finding 
that the arterial-renal vein blood glucose concentration difference in the post-
absorptive state is near zero. This is not the case however in more prolonged 
fasting conditions and during hypoglycemia, when a net contribution of the kidney 
to systemic glucose appearance has been demonstrated. The glucose extracted in 
the distal nephron is directed either towards glycogen synthesis for storage or to 
oxidative pathways, depending upon the local energy demands.  
                   Renal glycogen accumulation is thought to provide for immediate local 
energy needs, when blood-borne glucose supply lags behind. The renal oxidation 
of glucose can be partial the release of lactate and ATP, or complete, a 
mitochondrial process that yields H2O, CO2 and ATP. Partial anaerobic glucose 
oxidation is more prevalent in hypoxic medullary renal conditions. Renal glucose 
utilization occurs exclusively in distal tubular cells and, in the absence of glucose-
6-phospatase activity no glucose is released back into the interstitial fluid. 
Moreover, the small amount of glucose utilized distally does not affect the total 
glucose load leaving the nephron into the renal veins. 
GLUCOSE HANDLING BY THE KIDNEY: 
                     The fate of the glucose filtered, reabsorbed and excreted in the urine 
in normal and hyperglycemic conditions depends upon the glomerular filtration 
rate, the prevalent plasma concentration of glucose and the total transport capacity 
of the proximal tubule. There is a linear relationship between the filtered glucose 
load at the glomerulus and plasma glucose and thus, the glucose appearance in the 
ultra filtrate will be higher or lower as plasma glucose concentration increases or 
decreases, respectively.41 
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                 The proximal tubular reabsorption rate, on the other hand is only linear 
with the glucose load reaching the luminal membrane within a "normal" glycemic 
range. Once the maximum tubular reabsorption capacity of the kidney (Tmax,) is 
attained the transport process becomes saturated and glucose spills into the urine. It 
is worth mentioning that since the Tmax for glucose varies considerably among the 
nearly 2 millions nephrons in both kidneys, the maximum transport capacity is 
actually a "splay" or a range of values estimated to be around the calculated Tmax.  
                    The Tmax can be determined by artificially elevating plasma glucose 
levels in a stepwise fashion up to 400-500 mg/dl with simultaneous measurements 
of the glomerular filtration rate, plasma and urine glucose concentrations, and urine 
output at given intervals. In individuals with normal kidney function, the calculated 
maximum tubular glucose transport has been reported between 350-450 mg/min, 
which corresponds to mean venous glucose concentration in the range of 180-200 
mg/dl. 
                     Hence, the normal renal threshold (TmG) is often referred to as the 
venous plasma glucose concentration ~180 mg/dl. Once this value is exceeded the 
SGLT system saturation transport capacity is passed and glycosuria ensues. TmG 
varies with changes in glomerular filtration rates such that during pregnancy or 
with a unilateral kidney, when glomerular filtration rates increase, glucosuria will 
occur at plasma glucose concentrations below 180 mg/dl (lower TmG). 
Conversely, when glomerular filtration decreases such as in chronic kidney 
disease, glucosuria is seen at plasma glucose levels higher than 220 mg/dl. Of 
additional interest, some apparently healthy individuals inherit a genetic 
abnormality characterized by a defective SGLT transport system and thus, have 
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constant glycosuria with normal glomerular filtration rates and in conditions of 
normoglycemia.42 
                    The observation that the maximum tubular glucose reabsorption rate 
and the saturation capacity are markedly affected by chronic hyperglycaemia has 
provided the basis for a novel approach in the treatment of diabetes. Exposure to 
hyperglycemia is reportedly accompanied by an increase in tubular TmG, reflecting 
enhanced maximum glucose transport capacity and reabsorption. As a 
consequence, the appearance of glucose in the urine tends to occur at plasma 
glucose concentrations above the normal renal threshold of 180-200 mg/dl in 
patients with diabetes. 
                    (Tmax) was expanded and the renal threshold augmented in patients 
with type 2 diabetes by 20-40%.  More recent data derived from in vitro studies 
using cultures of proximal renal tubular cells collected from urine samples of 
subjects with and without diabetes fully supported these observations. In these 
experiments proximal tubular cells from patients with diabetes were shown to have 
increased mRNA expression and SGLT-2 protein content. Moreover, using a 
radio-labelled glucose analogue functional assay these cells also exhibited an 
elevated glucose transport capacity. Altogether, these results were interpreted as an 
indication that there is a maladaptive response of the kidney to hyperglycemia in 
diabetes mellitus. It has been speculated that by increasing glucose reabsorption 
rates, the kidney helps to maintain the abnormal status of hyperglycemia, which 
may in turn lead to further maladaptation. 
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INHIBITORS OF TUBULAR GLUCOSE REABSORPTION: 
                     The possibility that the diabetic kidney perpetuates hyperglycemia 
gave rise to the notion that agents capable of inhibiting renal glucose reabsorption 
might be useful in lowering blood glucose - SGLT inhibitors would reduce the 
tubular capacity for glucose reabsorption and promote glucosuria at lower plasma 
glucose levels (low Tm glucose). These findings suggested that with adequate 
chemical blockade of the SGLT transport activity, the renal threshold for glucose 
reabsorption could be decreased and better glycemic control achieved in patients 
with diabetes.43 
                   Many agents with SGLT inhibitor properties were obtained by 
techniques capable of chemically modifying the parent compound phlorizin 
("second generation agents"). Initially in vitro experiments in cultured cell lines 
expressing human SGLT-1 and SGLT-2 transporters were conducted to determine 
the degree of selectivity of any given SGLT inhibitor using radio-ligand binding 
assays.  
                   By the recent findings in humans revealing that orally ingested 
selective SGLT-2 inhibitors must first interact with the SGLT-1 transporters at the 
brush-border membrane of enterocytes. Because the enterocytes containing the 
SGLT-1 transporters are exposed to a greater load of the SGLT-2 specific 
inhibitors inside the gut, the binding affinity and thus, the selectivity is lost. As a 
result, the activity of the sodium-glucose/galactose co-transport process as a whole 
is reduced and there is a transient decline in the intestinal absorption of these 
sugars. The selectivity for the renal SGLT-2 transporters is nevertheless regained 
after partial splanchnic clearance and with lower circulating plasma drug levels. 
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                     Once selective inhibitors reach the kidney via the systemic arterial 
blood circulation, they bind avidly to SGLT-2 transporters in the luminal tubular 
membrane. In contrast, at much lower concentrations the binding affinity of these 
agents for the SGLT-1 transporter located downstream in the same area is severely 
diminished and no inhibition of the SGLT-1 activity in the kidney is detected. 
Following an insulin-independent decline in blood glucose, SGLT-2 inhibition is 
also accompanied by mild improvement in insulin sensitivity, which represents an 
additional mechanism by which these agents contribute to glycemic control in 
patients with type 2 diabetes. Moreover, recent findings reported in a SGLT-2 
knockout mouse model provide evidence for an alternative approach to improving 
glycemic control and reducing insulin sensitivity with preservation of beta-cell 
function, by simply reducing the renal threshold and promoting renal glycosuria.44 
CLINICAL PHARMACOLOGY AND PHARMACOKINETICS: 
                      The maximum inhibitory effect achievable on the renal glucose re-
uptake with the use of selective blockade of the tubular SGTL-2 transporter 
activity in humans has been reported at 30-50%. It has been postulated that the 
efficacy of these agents is somewhat limited, in part because of the competitive 
nature of the inhibitory binding process. There is also the possibility that very low 
levels of the active drug reach the tubular luminal membrane, the main site of the 
drug action. Finally, and perhaps most importantly, the extent to which a 
compensatory enhancement in the glucose reabsorption capacity of the SGLT-1 
co-transporter or by a yet unidentified tubular glucose transport system, located 
downstream contributes to the low effectiveness of these agents has not been 
defined. Once plasma steady-state concentrations of the SGLT inhibitor are 
reached (4 to 5 days), the total amount of glucose excreted in the urine is around 
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50-80 grams per day. This results from the partial blockade of the SGLT-2 co-
transporter and reflects a shift to the left in the maximum tubular transport capacity 
with a substantial decrease in the renal threshold [TmG].  
                    Clinical observational studies conducted in healthy non-diabetic and in 
diabetic subjects have indicated that the appearance of glucosuria can be detected 
within 8-16 weeks after the oral intake of the first dose of an SGLT-2 inhibitor. 
Actually, it has been estimated that following a short therapy period with SGLT-2 
inhibitors glucosuria can be detected both in subjects with and without diabetes at 
plasma glucose values ranging anywhere from 40-120 mg/dl. This remarkable shift 
in the renal threshold for glucose reabsorption contributes to a significant decrease 
in circulating plasma glucose, which is accomplished with a daily loss of 200-320 
calories.45 
                     These changes combined can provide much desired benefits for obese 
patients with diabetes. The decline in plasma glucose concentration following the 
use of SGLT inhibitors has been recently reported to be attenuated by a rise in 
plasma glucagon accompanied by an elevation in endogenous glucose production. 
These findings were documented in subjects who had received SGLT-2 inhibitors 
for a short period of time and who had experienced a drop in plasma glucose 
levels, but with no evidence of hypoglycemia. These intriguing observations have 
raised new questions regarding potential interactions of the kidney and liver in 
glucose regulation and counter-regulation. 
                      Following oral administration SGLT-2 inhibitors are rapidly 
absorbed with peak plasma concentrations (median T max ) occurring 1-2 hours 
post-dose. Plasma C max and the area under the curve (AUC) increase in a dose-
proportional manner with apparent terminal half-life (t 1/2 ) of varying from 10 up 
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to 13 hours. The active drug reaches a steady-state usually within 4 to 5 days. The 
major metabolic elimination of SGLT-2 inhibitors is via hepatic glucuronidation 
and the inactive metabolites are released into peripheral circulation. There is 
minimal CYP3A4-mediated oxidative metabolic degradation. Thus, clinically 
relevant effects of other drugs on the pharmacokinetics of SGLT-2 inhibitors via 
cytochrome P450 are unlikely to occur. Also, since the CYP450 enzyme system is 
not induced and is only minimally attenuated by SGLT-2 inhibitors only negligible 
changes in drugs utilizing the same hepatic metabolic processes have been 
reported.46 
                      In contrast, a decrease in total exposure to active SGLT-2 inhibitors 
occurs when UGT (glucuronosyl transferase) inducers, such as rifampin, phenytoin 
and phenobarbital are co-administered. Plasma digoxin levels tend to increase and 
require closer monitoring when used in combination with SGLT-2 inhibitors. 
When using oral radio-labeled SGLT-2 inhibitors in normal healthy volunteers 
nearly 50% of the active drug is recovered in feces together with minor amounts 
(less than 10%) of some inactive metabolites; less than 1% of the oral dose is 
excreted intact in the urine. 
SAFETY AND EFFICACY OF SGLT INHIBITORS: 
                      The fact that selective inhibitors of SGLT-2 lower plasma glucose 
concentration via an insulin-independent manner, and thus with minimal risk of 
hypoglycemia, combined with the potential to induce simultaneous body weight 
loss has generated considerable clinical interest. The mean reported decrease in the 
glycosylated hemoglobin (HbA1c) values was approximately 1.0%, which was 
initially documented over a period of 6 months. More recent preliminary data have 
confirmed that these changes can be sustained with safety up to 4 years. The 
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degree of glycemic control attained with SGLT-2 inhibitors was shown to be either 
comparable or superior  the decrease in blood glucose can be attained within a 
wide range of plasma glucose concentration, whether early in the disease  the 
tubular reabsorption capacity is abnormally enhanced has not been fully 
determined. Moreover, with limited clinical experience and considering the added 
cost this class of drugs is more likely to be used later, rather than earlier in the 
treatment of type 2 diabetes. The possibility nevertheless of combining these 
agents with other well-established anti-diabetic drugs, oral and injectables seems 
more reasonable. Taking into account the unique mechanism of action of SGLT-2 
inhibitors, maybe they are best if indicated in patients with poorly-controlled type 
2 diabetes in whom oral treatment has been exhausted and the initiation of 
injectable agents or insulin replacement therapy is eminent. 
                      Body weight loss was anticipated and has occurred in almost all 
diabetic patients who received therapy with SGLT-2 inhibitors in pivotal clinical 
trials. The usual amount of body weight lost was reported in the range of 2 to 4 
kilograms over a period of observation of 6 months, with only a few outliers. 
Interestingly, studies using other drugs that promote body weight usually provide 
results with noticeable individual variability, whereas SGLT-2 inhibitors tend to 
induce nearly equal body weight loss in just about everyone treated. A recent study 
indicated that the majority of the weight reduction was due to the loss of body fat 
mass, ~50% each in the abdominal and subcutaneous fat depots, with minimal 
changes in lean body mass.  
                      The stabilization of the body weight achieved 6 months after the 
initiation of therapy, which has been confirmed to persist up to 4 years with the 
continued use of SGLT-2 inhibitors is regarded as a remarkable accomplishment 
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and provides further reassurance to those who manage obese type 2 diabetic 
patients. Whether a later compensatory increase in appetite and/or a change in 
energy expenditure will occur in response to the loss of calories in the urine over 
longer periods of time. As a reminder, these agents are not approved for the sole 
treatment of overweight and obese individuals who do not have a diagnosis of type 
2 diabetes.47 
                      The low incidence of hypoglycemia is a clinically relevant and 
important characteristic associated with the use of SGLT-2 inhibitors in the 
management of type 2 diabetes. This results from the fact that the mechanisms 
underlying the glucose-lowering effect of a partial blockade of the tubular glucose 
re-uptake are insulin-independent and do not involve direct changes in insulin 
secretion. 
                       Furthermore, the rate of urinary glucose excretion is proportionate to 
the circulating plasma glucose concentration and thus, it becomes almost negligible 
in conditions of very low plasma glucose concentrations. In contrast, when SGLT-
2 inhibitors are used in combination with insulin secretagogues  or together with 
insulin injections the risk for hypoglycemia is magnified.  
                       Some important and a few unexpected findings have been reported 
in patients with type 2 diabetes who were exposed to various SGLT-2 inhibitors in 
clinical trials. Following initial treatment a transient period of polyurea, urinary 
frequency with increased thirst, often characterized as a simple state of dehydration 
was described in 3-5% of all study subjects. Two-thirds of these individuals had 
symptoms of postural dizziness and most of them had documented orthostatic 
hypotension. The majority recovered uneventfully, presumably because blood 
volume and fluid balance were appropriately corrected by alternate renal and some 
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other mechanisms. Of note, dehydration and orthostatism was more common in 
elderly diabetic patients who were taking anti-hypertensive drugs and/or diuretics. 
                       Despite the transient nature of these acute hemodynamic events, 
greater caution and a special attention to this vulnerable population will be 
required by prescribing physicians and health care providers. For reasons that are 
not entirely clear, a slight and consistent decrease in systolic and diastolic blood 
pressure has been recorded in nearly all diabetic patients treated with SGLT-2 
inhibitors for at least 6 months.48 
                       Whether this potential beneficial effect can be related to changes in 
blood volume and hydration status and/or to a direct or indirect vascular dilation 
property of SGLT-2 inhibitors remains undetermined. 
                       Rare cases of mild hyperkalemia following the administration of 
SGLT-2 inhibitors have been reported, primarily in patients with some degree of 
renal insufficiency. Nearly all diabetic patients who experienced serum potassium 
elevations were using potassium-sparing diuretics, angiotensin-converting enzyme 
inhibitors or angiotensin receptor blocking agents.  
                      Considering the recommendations for the use of SGLT-2 inhibitors 
are limited to lower doses and should be given only to diabetic patients with 
estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73 m2, the 
occurrence of hyperkalemia is expected to be a rare event. Because of pure 
inefficacy, these agents are not indicated in patients with advanced end-stage renal 
disease and those on renal dialysis. In case of inadvertent drug overdose and 
intoxication, SGLT-2 inhibitors cannot be removed from the circulation efficiently 
by hemodialysis.  
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                     In patients with mild-to-moderate hepatic insufficiency, nonetheless 
there is no need for adjustments in dose, although the safety and efficacy of these 
SGLT-2 inhibitors have never been tested in patients with severe hepatic 
insufficiency. Also, the use of SGLT-2 inhibitors is contra-indicated during 
pregnancy and in lactating diabetic women, since newborn animals exposed to this 
agent exhibit a multitude of kidney and urogenital malformations.  
                       The diagnosis was confirmed in women exposed to dapagliflozin for 
less than one year and in two cases the presence of breast cancer was documented 
within the first eight weeks of treatment. Based on these observations, the FDA 
concluded that there were too few events to establish causality, a decision 
supported by the fact that no carcinogenicity or mutagenic signal has been 
described during pre-clinical animal studies. Although the accumulation of large 
amounts of glucose in the bladder urine over time cannot be entirely rule out as a 
putative carcinogenic factor, it is reassuring to know that SGLT-2 transporter 
proteins are not expressed either in human bladder or in breast tissue.49 
                      There was a noticeable increase in the incidence of urinary tract and 
genital infections in patients with type 2 diabetes who were treated with SGLT-2 
inhibitors reported in all clinical trials. Nearly all infections were limited to the 
lower urinary tract and were reported in ~8-13% of participants receiving SGLT-2 
inhibitors, but only in ~3-8% of those randomized to either placebo or a 
comparator drug. Similarly, genital infections developed in ~12-15% of patients 
taking SGLT-2 inhibitors, whereas those using placebo or a comparator drug had 
an incidence no higher than ~5%. 
                        These observations were derived from studies that included more 
than 10,000 patients with type 2 diabetes followed by at least 2 years of exposure 
INTRODUCTION 
 
DEPARTMENT OF PHARMACY PRACTICE Page 58 
 
to various SGLT-2 inhibitors. Women, especially those with a positive past 
medical history were more commonly affected, although the vast majority of 
infections resolved with standard treatment, did not require hospital admissions, 
and recurrences were infrequent. Actually, many of the participants who developed 
urinary and genital infections elected to continue with the treatment, particularly 
those in whom glucose control and body weight loss were apparent. Less than 2% 
of all patients treated with SGLT-2 inhibitors who developed genital mycosis, 
namely balano-postitis, were uncircumcised men.  
                        This is an autossomal recessive disorder with either complete 
deficiency or decreased affinity for the SGLT-2 co-transporter protein. The 
genetics of "familial renal glucosuria" have been studied extensively and 21 
different mutations in the gene for SGLT2 were detected. Homozygous individuals 
tend to have glycosuria that varies from 15 up to 200 g/day, whereas pure 
heterozygous family members have either mild glycosuria or none at all. Because 
this condition is characterized by persistent urinary glucose excretion, even within 
the normal range of plasma glucose concentration these individuals have difficulty 
maintaining body weight.50 
                          There is no evidence of renal glomerular or tubular dysfunction, as 
assessed by kidney function and renal histological evaluations. Hypoglycemia is 
uncommon and the incidence of diabetes mellitus, chronic renal insufficiency and 
urinary tract infections is comparable to the general population. The diagnosis of 
"familial renal glucosuria" must be distinguished however from other complex 
tubular disorders that can be associated with some morbidity.  
                         The kidney plays an important role in glucose homeostasis, 
contributes to glucose regulation and counter-regulation, and in sparing glucose 
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also helps to preserve the energy balance. These remarkable functions are achieved 
by an active proximal tubular mega-transport system that promotes complete 
glucose reabsorption and by the minimal intrinsic glucose production that often 
matches renal glucose utilization. Chronic hyperglycemia is associated with an 
increase in renal threshold and renal glucosuria occurs at higher than normal 
plasma glucose concentrations. 
                       As a consequence, specific inhibition of the high capacity renal 
sodium-glucose co-transporter (SGLT-2) has emerged as a potential 
pharmacological intervention, which by decreasing tubular glucose reabsorption 
rates induces glucosuria and reduces blood glucose levels. In addition, continuous 
loss of calories in the urine is accompanied by a sustained decrease in body 
weight/fat in obese patients with type 2 diabetes. Initial observations in pre-clinical 
studies and in clinical trials have raised expectations for the utilization of SGLT-2 
inhibitors in the treatment of type 2 diabetes. The data collected so far 
demonstrating a clinically significant glucose-lowering effect, body weight loss 
and negligible risk of hypoglycemia in patients treated with this novel class of 
drugs are very consistent.51 
                       The development of transient polyuria with dehydration and the 
occasional hypotension, particularly in elderly diabetic patients is of concern. The 
high frequency of urinary tract infections and genital mycosis requires close 
monitoring. Lower doses of SGLT-2 can be used safely in individuals with mild-
to-moderate, but not in those with severe and end-stage renal insufficiency. 
Whether there is any long-term damage to the kidney is unknown and 
cardiovascular benefits are yet to be demonstrated with the use of these novel 
agents. Some SGLT-2 inhibitors are now approved for the treatment of type 2 
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diabetes, either as monotherapy or in combination with other anti-diabetic 
medications. As long as patients can tolerate these agents, given all that we know 
today, SGLT-2 inhibitors if used with caution and in the proper patient may 
provide an additional safe and efficacious therapeutic option in the management of 
type 2 diabetes. 
PLEIOTROPIC EFFECTS: 
                   Sodium-glucose co-transporter-2 inhibitors use leads to a reduction in 
body weight, ranging from about 1 to 5 kg . A greater fall is seen in patients with 
long-standing diabetes and in those with a higher baseline weight. This weight loss 
is sustained after up to 2 years of use of dapagliflozin, and may be linked to a 
reduction in insulin dose requirements of patients with long-standing diabetes.  
                   While it may be argued that weight loss is because of volume 
depletion, it has been shown that two-thirds of the decreased weight is lost from fat 
mass (especially visceral abnormal fat), as compared to lean mass . An initially 
rapid decline in weight is followed by a slower rate of weight loss, and is also 
marked by a reduction in weight circumference. Concomitant use of SGLT2i can 
attenuate or neutralize weight gain due to insulin, if given in combination with 
insulin. 
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       FIGURE 14: PLEIOTROPIC EFFECT OF SGLT2 INHIBITORS 
                    Sodium-glucose co-transporter-2 inhibitors also cause significant 
reductions in both systolic and diastolic blood pressure (BP). These changes are 
relatively more prominent for systolic BP, are not dose dependent, and are not 
characterized by concomitant tachycardia or symptoms of hypotension/syncope in 
most of the cases. The effects on BP seem to be independent of glycemic or body 
weight reduction, and are greater in patients with high baseline systolic BP. BP 
reduction with SGLT2i occurs due to osmotic diuresis initially, and to local rennin-
angiotensin system inhibition later on. 
                        Uric acid levels, a marker of metabolic dysfunction, are markedly 
reduced (5.9–17.8%) by SGLT2i, with the effect sustained for 2 years.The drugs 
may affect uric acid excretion directly, by acting on its transport system, or 
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indirectly, but reducing sodium reabsorption in the PCT. The beneficial impact of 
SGLT2i on uric acid is attenuated if insulin is co-prescribed. 
                       Renal hyperfiltration has been found to be closely associated with 
the development of diabetic nephropathy (DN). Pooled data from 2 randomized 
clinical trials including 600 patients with normo- or microalbuminuria followed up 
for 4 years which demonstrated that hyperfiltration has central role in pathogenesis 
of DN. SGLT2 is one of the main determinants of glomerular hyperfiltration and 
blockade of SGLT2 has potential nephroprotective action.52 
THE FUTURE OF SGLT2 INHIBITORS:   
 
                         Initial evidence that augmenting renal glucose excretion could lead 
to improved glycemic control has come from  studies using phlorizin, a molecule 
originally isolated from the bark of apple tree, which inhibits both the SGLT2/1. 
Withdrawal of phlorizin was associated with a return to the diabetic state. 
Subsequently many selective SGLT2 inhibitors like Dapagliflozin, Canagliflozin, 
Sergliflozin, Remogliflozin,  in development and ongoing trials. Dapagliflozin is 
approximately 1,200 times more selective for SGLT2 over SGLT1. An in vitro 
study revealed that dapagliflozin exhibited around 30 times greater potency against 
SGLT2 in humans than phlorizin, and approximately 4 fold less potency versus 
phlorizin against human SGLT1. It has demonstrated promise as mono therapy and 
as synergistic combination therapy with the currently available agents.53 
                       It has also shown to reduce total body weight, predominantly by 
reducing fat mass, visceral and subcutaneous adipose tissue in inadequately 
controlled T2DM; and therefore improve glycemic control, stabilize insulin dosing, 
and reduce weight without increasing major hypoglycemic episodes. Prevention of 
obesity-associated hyperglycemia, improved glucose intolerance, and increased 
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glucose-stimulated insulin secretion support SGLT2 inhibition as a viable insulin-
independent treatment and prevention of T2DM, and perhaps T1DM. However, the 
safety issue remains the most important parameter determining the future of any 
drug in development. By virtue of their nature, SGLT2 inhibitors cause glycosuria 
that can lead to urinary tract and genital infections, electrolyte imbalances, and 
increased urinary frequency. The most frequently reported adverse events in phase 
II and III trials include constipation, diarrhea, nausea, urinary frequency, and 
genitourinary infections involving UTIs and vulvovaginal infections. Although 
dapagliflozin appeared to be safe and well tolerated in trials until recently, it has 
not yet attained FDA approval, due to unanswered questions regarding safety. The 
U.S. Food and Drug Administration has recently approved Canagliflozin, used 
with diet and exercise, to improve glycemic control in adults with type 2 diabetes. 
Canagliflozin treatment improved glycemic control, reduced body weight and was 
generally well tolerated in subjects with T2DM inadequately controlled with diet 
and exercise. A randomized, placebo-controlled study has shown that 
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal 
glucose absorption in addition to increasing urinary glucose excretion. 
Canagliflozin has also improved glycemic control and was generally well tolerated 
in subjects with T2DM and Stage 3 CKD.54 
                SGLT2 inhibitors are an exciting novel class of antidiabetic agents which 
are effective at reducing glycaemia, induce weight loss and reduce blood pressure 
with no severe adverse effects. The most frequent adverse events are an increase in 
urinary and genital infections, though this rarely leads to treatment discontinuation. 
SGLT2 inhibitors also have a very low intrinsic capacity to cause hypoglycemia. 
Moreover, the mechanism of action of SGLT2 inhibitors is independent of insulin 
secretion or action. The favorable metabolic effects of the SGLT2 inhibitors makes 
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this class of oral antidiabetic agents an attractive new tool in the battle against 
T2DM. Nevertheless there are some issues such as cardiovascular safety and 
cancer risk which require close monitoring post marketing. Finally, the effect of 
SGLT2 inhibition in patients with impaired kidney function needs more research. 
There might be a protective effect on kidney function which would be an exciting 
new way to prevent diabetic nephropathy. However, the efficacy of the drug seems 
to decline as kidney function becomes more impaired. Further studies are also 
ongoing investigating the effect of SGLT2 inhibition in patients with type 1 
diabetes, when this might also be protective for the kidney.55 
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CANAGLIFLOZIN56 
CHEMICAL NAME: (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-
thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate. 
CHEMICAL FORMULA: C24H25FO5S•½ H2O. 
STRUCTURAL FORMULA: 
                           
CANAGLIFLOZIN 
DESCRIPTION: The molecular weight is 453.53. 
                Inactive ingredients of the core tablet are croscarmellose sodium, 
hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and 
microcrystalline cellulose. The magnesium stearate is vegetable-creditd. The 
tablets are finished with a commercially available film-coating consisting of the 
following excipients: polyvinyl alcohol (partially hydrolyzed), titanium dioxide, 
macrogol/PEG, talc, and iron oxide yellow, E172 (100 mg tablet only). 
DOSAGE FORM: Tablet 
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MECHANISM OF ACTION: 
                  Sodium-glucose co -transporter 2 (SGLT2), expressed in the 
proximal renal tubules, is responsible for the majority of the reabsorption of 
filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. 
By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and 
lowers the renal threshold for glucose (RTG), and thereby increases urinary 
glucose excretion (UGE). 
CLINICAL PHARMACOLOGY: 
PHARMACODYNAMICS: 
                      Following single and multiple oral doses of canagliflozin in 
patients with type 2 diabetes, dose-dependent decreases in the renal threshold 
for glucose (RTG) and increases in urinary glucose excretion were observed. 
From a starting RTG value of approximately 240 mg/dL, canagliflozin at 100 
mg and 300 mg once daily suppressed RTG throughout the 24-hour period. 
Maximal suppression of mean RTG over the 24-hour period was seen with the 
300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 
diabetes in Phase 1 studies. The reductions in RTG led to increases in mean 
UGE of approximately 100 g/day in subjects with type 2 diabetes treated with 
either 100 mg or 300 mg of canagliflozin. In patients with type 2 diabetes given 
100 mg to 300 mg once daily over a 16-day dosing period, reductions in RTG 
and increases in urinary glucose excretion were observed over the dosing 
period. In this study, plasma glucose declined in a dose-dependent fashion 
within the first day of dosing. In single-dose studies in healthy and type 2 
diabetic subjects, treatment with canagliflozin 300 mg before a mixed-meal 
delayed intestinal glucose absorption and reduced postprandial glucose. 
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PHARMACOKINETICS: 
                  The pharmacokinetics of canagliflozin is similar in healthy subjects 
and patients with type 2 diabetes. Following single-dose oral administration of 
100 mg and 300 mg of CANAGLIFLOZIN, peak plasma concentrations 
(median Tmax) of canagliflozin occurs within 1 to 2 hours post-dose. Plasma 
Cmax and AUC of canagliflozin increased in a dose-proportional manner from 
50 mg to 300 mg. The apparent terminal half-life (t½) was 10.6 hours and 13.1 
hours for the 100 mg and 300 mg doses, respectively. Steady-state was reached 
after 4 to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg 
ABSORPTION 
                  The mean absolute oral bioavailability of canagliflozin is 
approximately 65%. Co-administration of a high-fat meal with canagliflozin had 
no effect on the pharmacokinetics of canagliflozin; therefore, 
CANAGLIFLOZIN may be taken with or without food. However, based on the 
potential to reduce postprandial plasma glucose excursions due to delayed 
intestinal glucose absorption, it is recommended that CANAGLIFLOZIN be 
taken before the first meal of the day. 
DISTRIBUTION 
                    The mean steady-state volume of distribution of canagliflozin 
following a single intravenous infusion in healthy subjects was 83.5 L, 
suggesting extensive tissue distribution. Canagliflozin is extensively bound to 
proteins in plasma (99%), mainly to albumin. Protein binding is independent of 
canagliflozin plasma concentrations.. 
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METABOLISM 
             O-glucuronidation is the major metabolic elimination pathway for 
canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two 
inactive O-glucuronide metabolites. 
EXCRETION 
               Following administration of a single oral [14C] canagliflozin dose to 
healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose 
was recovered in feces as canagliflozin, a hydroxylated metabolite, and an O-
glucuronide metabolite, respectively. Enterohepatic circulation of canagliflozin 
was negligible. 
                    Approximately 33% of the administered radioactive dose was 
excreted in urine, mainly as O-glucuronide metabolites (30.5%). Less than 1% 
of the dose was excreted as unchanged canagliflozin in urine. Renal clearance of 
canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min. 
                 The recommended starting dose of CANAGLIFLOZIN 
(canagliflozin) is 100 mg once daily, taken before the first meal of the day.. 
PATIENTS WITH RENAL IMPAIRMENT 
                The dose of CANAGLIFLOZIN is limited to 100 mg once daily in 
patients with moderate renal impairment with an eGFR of 45 to less than 60 
mL/min/1.73 m². 
                 CANAGLIFLOZIN should not be initiated in patients with an eGFR 
less than 45 mL/min/1.73 m². 
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                   Assessment of renal function is recommended prior to initiation of 
CANAGLIFLOZIN therapy and periodically thereafter. CANAGLIFLOZIN 
should be discontinued when eGFR is persistently less than 45 mL/min/1.73 m². 
CONCOMITANT USE WITH UDP-GLUCURONOSYL TRANSFERASE 
(UGT) ENZYME INDUCERS 
                      If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, 
ritonavir) is co-administered with CANAGLIFLOZIN, consider increasing the 
dosage to 300 mg once daily in patients currently tolerating CANAGLIFLOZIN 
100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and 
require additional glycemic control.Consider another antihyperglycemic agent 
in patients with an eGFR of 45 to less than 60 mL/min/1.73 m² receiving 
concurrent therapy with a UGT inducer. 
INDICATIONS: 
 CANAGLIFLOZIN® (canagliflozin) is indicated as an adjunct to diet 
and exercise to improve glycemic control in adults with type 2 diabetes 
mellitus. 
 LIMITATION OF USE 
 CANAGLIFLOZIN is not recommended in patients with type 1 diabetes 
mellitus or for the treatment of diabetic ketoacidosis. 
CONTRAINDICATIONS: 
 History of a serious hypersensitivity reaction to CANAGLIFLOZIN, such 
as anaphylaxis or angioedema. 
 Severe renal impairment (eGFR less than 30 mL/min/1.73 m²), end stage 
renal disease (ESRD), on or patients dialysis. 
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WARNINGS AND PRECAUTIONS: 
HYPOTENSION 
                  CANAGLIFLOZIN causes intravascular volume contraction. 
Symptomatic hypotension can occur after initiating CANAGLIFLOZIN. 
Particularly in patients with impaired renal function (eGFR less than 60 
mL/min/1.73 m²), elderly patients, patients on either diuretics or medications 
that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin 
converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or 
patients with low systolic blood pressure.. 
KETOACIDOSIS 
                  Reports of ketoacidosis, a serious life-threatening condition 
requiring urgent hospitalization have been identified in postmarketing 
surveillance in patients with type 1 and type 2 diabetes mellitus receiving 
sodium glucose co-transporter-2 (SGLT2) inhibitors, including 
CANAGLIFLOZIN. CANAGLIFLOZIN is not indicated for the treatment of 
patients with type 1 diabetes mellitus. 
IMPAIRMENT IN RENAL FUNCTION 
                 CANAGLIFLOZIN increases serum creatinine and decreases eGFR. 
Patients with hypovolemia may be more susceptible to these changes. Renal 
function abnormalities can occur after initiating CANAGLIFLOZIN. More 
frequent renal function monitoring is recommended in patients with an eGFR 
below 60 mL/min/1.73 m². 
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HYPERKALEMIA 
                  CANAGLIFLOZIN can lead to hyperkalemia. Patients with 
moderate renal impairment who are taking medications that interfere with 
potassium excretion, such as potassium-sparing diuretics, or medications that 
interfere with the renin-angiotensin-aldosterone system are at an increased risk 
of developing hyperkalemia. Monitor serum potassium levels periodically after 
initiating CANAGLIFLOZIN in patients with impaired renal function and in 
patients predisposed to hyperkalemia due to medications or other medical 
conditions. 
UROSEPSIS AND PYELONEPHRITIS 
                  There have been postmarketing reports of serious urinary tract 
infections including urosepsis and pyelonephritis requiring hospitalization in 
patients receiving SGLT2 inhibitors, including CANAGLIFLOZIN.  
HYPOGLYCEMIA WITH CONCOMITANT USE WITH INSULIN AND 
INSULIN SECRETAGOGUES 
                    Insulin and insulin secretagogues are known to cause 
hypoglycemia. CANAGLIFLOZIN can increase the risk of hypoglycemia when 
combined with insulin or an insulin secretagogue. 
GENITAL MYCOTIC INFECTIONS 
                   CANAGLIFLOZIN increases the risk of genital mycotic infections. 
Patients with a history of genital mycotic infections and uncircumcised males 
were more likely to develop genital mycotic infections. Monitor and treat 
appropriately. 
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HYPERSENSITIVITY REACTIONS 
                  Hypersensitivity reactions, including angioedema and anaphylaxis, 
have been reported with CANAGLIFLOZIN. These reactions generally 
occurred within hours to days after initiating CANAGLIFLOZIN. If 
hypersensitivity reactions occur, discontinue use of CANAGLIFLOZIN; treat 
and monitor until signs and symptoms resolve. 
BONE FRACTURE 
               An increased risk of bone fracture, occurring as early as 12 weeks after 
treatment initiation, was observed in patients using CANAGLIFLOZIN.  
INCREASES IN LOW-DENSITY LIPOPROTEIN (LDL-C) 
               Dose-related increases in LDL-C occur with CANAGLIFLOZIN. 
Monitor LDL-C and treat if appropriate after initiating CANAGLIFLOZIN 
ADVERSE REACTION: 
The following important adverse reactions are described below and elsewhere in 
the labeling: 
 Hypotension. 
 Ketoacidosis.  
 Impairment in Renal Function  
 Hyperkalemia  
 Urosepsis and Pyelonephritis.  
 Hypoglycemia with Concomitant Use with Insulin and Insulin 
Secretagogues. 
 Genital Mycotic Infections. 
 Hypersensitivity Reactions. 
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 Bone Fracture. 
 Increases in Low-Density Lipoprotein (LDL-C). 
DRUG INTERACTIONS 
UGT ENZYME INDUCERS 
RIFAMPIN:  
                 Co-administration of canagliflozin with rifampin, a nonselective 
inducer of several UGT enzymes, including UGT1A9, UGT2B4, decreased 
canagliflozin area under the curve (AUC) by 51%. This decrease in exposure to 
canagliflozin may decrease efficacy  
DIGOXIN 
                There was an increase in the AUC and mean peak drug concentration 
(Cmax) of digoxin (20% and 36%, respectively) when co-administered with 
CANAGLIFLOZIN 300 mg. Patients taking CANAGLIFLOZIN with 
concomitant digoxin should be monitored appropriately. 
POSITIVE URINE GLUCOSE TEST 
                    Monitoring glycemic control with urine glucose tests is not 
recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase 
urinary glucose excretion and will lead to positive urine glucose tests.  
STORAGE: 
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). 
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DAPAGLIFLOZIN57 
CHEMICAL NAME: D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-
ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, 
hydrate(1:1:1). 
CHEMICAL FORMULA: C21H25ClO6•C3H8O2•H2O 
STRUCTURAL FORMULA: 
                      
DESCRIPTION 
                The molecular weight is 502.98. microcrystalline cellulose, anhydrous 
lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the 
film coating contains the following inactive ingredients: polyvinyl alcohol, 
titanium dioxide, polyethylene glycol, talc, and yellow iron oxide. 
DOSAGE FORM: Tablet 
MECHANISM OF ACTION:  
                   Sodium-glucose cotransporter 2 (SGLT2), expressed in the 
proximal renal tubules, is responsible for the majority of the reabsorption of 
filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. 
By inhibiting SGLT2, Dapagliflozin reduces reabsorption of filtered glucose 
and lowers the renal threshold for glucose, and thereby increases urinary 
glucose excretion. 
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CLINICAL PHARMACOLOGY 
PHARMACODYNAMICS 
GENERAL 
                      Increases in the amount of glucose excreted in the urine were 
observed in healthy subjects and in patients with type 2 diabetes mellitus 
following the administration of Dapagliflozin. Dapagliflozin doses of 5 or 10 
mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in 
excretion of approximately 70 grams of glucose in the urine per day at Week 
12. This urinary glucose excretion with Dapagliflozin also results in increases in 
urinary volume. 
PHARMACOKINETICS 
ABSORPTION 
                 Following oral administration of Dapagliflozin, the maximum plasma 
concentration (Cmax) is usually attained within 2 hours under fasting state. The 
Cmax and AUC values increase dose proportionally with increase in 
Dapagliflozin dose in the therapeutic dose range. The absolute oral 
bioavailability of Dapagliflozin following the administration of a 10 mg dose is 
78%. Administration of Dapagliflozin with a high-fat meal decreases its Cmax by 
up to 50% and prolongs Tmax by approximately 1 hour. 
DISTRIBUTION 
                   Dapagliflozin is approximately 91% protein bound. Protein binding 
is not altered in patients with renal or hepatic impairment. 
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METABOLISM 
                  The metabolism of Dapagliflozin is primarily mediated by UGT1A9; 
CYP-mediated metabolism is a minor clearance pathway in humans. 
Dapagliflozin is extensively metabolized, primarily to yield Dapagliflozin 3-O-
glucuronide. 
ELIMINATION 
                    Dapagliflozin and related metabolites are primarily eliminated via 
the renal pathway. Following a single 50 mg dose of [14C]-Dapagliflozin, 75% 
and 21% total radioactivity is excreted in urine and faeces, respectively. In 
urine, less than 2% of the dose is excreted as parent drug. In faeces, 
approximately 15% of the dose is excreted as parent drug. The mean plasma 
terminal half-life (t½) for Dapagliflozin is approximately 12.9 hours following a 
single oral dose of DAPAGLIFLOZIN 10 mg. 
ROUTE OF ADMINISTRATION: Oral 
DOSAGE AND ADMINISTRATION: 
RECOMMENDED DOSING 
                 The recommended starting dose of DAPAGLIFLOZIN is 5 mg once 
daily, taken in the morning, with or without food. In patients tolerating 
DAPAGLIFLOZIN 5 mg once daily who require additional glycemic control, 
the dose can be increased to 10 mg once daily. 
PATIENTS WITH RENAL IMPAIRMENT: 
          Initiation of DAPAGLIFLOZIN is not recommended in patients with an 
eGFR less than 60 mL/min/1.73 m2. 
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No dose adjustment is needed in patients with mild renal impairment (eGFR of 
60 mL/min/1.73 m2 or greater). 
Use of DAPAGLIFLOZIN is not recommended in patients with an eGFR 
persistently between 30 and less than 60 mL/min/1.73 m2. 
DAPAGLIFLOZIN is contraindicated in patients with an eGFR less than 30 
mL/min/1.73 m2. 
INDICATIONS: 
DAPAGLIFLOZIN is indicated as an adjunct to diet and exercise to improve 
glycemic control in adults with type 2 diabetes mellitus. 
CONTRAINDICATIONS: 
 History of a serious hypersensitivity reaction to DAPAGLIFLOZIN. 
 Severe renal impairment, (eGFR less than 30 mL/min/1.73 m2) end-stage 
renal disease (ESRD), or patients on dialysis. 
WARNINGS AND PRECAUTIONS 
HYPOTENSION 
                  DAPAGLIFLOZIN causes intravascular volume contraction. 
Symptomatic hypotension can occur after initiating DAPAGLIFLOZIN  
particularly in patients with impaired renal function (eGFR less than 60 
mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before 
initiating DAPAGLIFLOZIN in patients with one or more of these 
characteristics, volume status should be assessed and corrected. Monitor for 
signs and symptoms of hypotension after initiating therapy. 
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KETOACIDOSIS 
                     Reports of ketoacidosis, a serious life-threatening condition 
requiring urgent hospitalization have been identified in postmarketing 
surveillance in patients with type 1 and type 2 diabetes mellitus receiving 
sodium-glucose cotransporter 2 (SGLT2) inhibitors, including 
DAPAGLIFLOZIN. DAPAGLIFLOZIN is not indicated for the treatment of 
patients with type 1 diabetes mellitus. 
                   Patients treated with DAPAGLIFLOZIN who present with signs 
and symptoms consistent with severe metabolic acidosis should be assessed for 
ketoacidosis regardless of presenting blood glucose levels as ketoacidosis 
associated with DAPAGLIFLOZIN may be present even if blood glucose levels 
are less than 250 mg/dL. If ketoacidosis is suspected, DAPAGLIFLOZIN 
should be discontinued, the patient should be evaluated and prompt treatment 
should be instituted. Treatment of ketoacidosis may require insulin, fluid and 
carbohydrate replacement. 
ACUTE KIDNEY INJURY AND IMPAIRMENT IN RENAL FUNCTION 
                      DAPAGLIFLOZIN causes intravascular volume contraction  
cause renal impairment. Before initiating DAPAGLIFLOZIN, consider factors 
that may predispose patients to acute kidney injury including hypovolemia, 
chronic renal insufficiency, congestive heart failure, and concomitant 
medications . 
                     DAPAGLIFLOZIN increases serum creatinine and decreases 
eGFR. Elderly patients and patients with impaired renal function may be more 
susceptible to these changes. Adverse reactions related to renal function can 
occur after initiating DAPAGLIFLOZIN. Renal function should be evaluated 
prior to initiation of DAPAGLIFLOZIN and monitored periodically thereafter.                      
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Use of DAPAGLIFLOZIN is not recommended in patients with an eGFR 
persistently between 30 and less than 60 mL/min/1.73 m2 and is contraindicated 
in patients with an eGFR less than 30 mL/min/1.73 m2. 
UROSEPSIS AND PYELONEPHRITIS 
                        There have been postmarketing reports of serious urinary tract 
infections including urosepsis and pyelonephritis requiring hospitalization in 
patients receiving SGLT2 inhibitors, including DAPAGLIFLOZIN. Treatment 
with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate 
patients for signs and symptoms of urinary tract infections and treat promptly, if 
indicated. 
HYPOGLYCEMIA WITH CONCOMITANT USE WITH INSULIN AND 
INSULIN SECRETAGOGUES 
                   Insulin and insulin secretagogues are known to cause hypoglycemia. 
DAPAGLIFLOZIN can increase the risk of hypoglycemia when combined with 
insulin or an insulin secretagogue, a lower dose of insulin or insulin 
secretagogue may be required to minimize the risk of hypoglycemia when these 
agents are used in combination with DAPAGLIFLOZIN. 
GENITAL MYCOTIC INFECTIONS 
                    DAPAGLIFLOZIN increases the risk of genital mycotic infections. 
Patients with a history of genital mycotic infections were more likely to develop 
genital mycotic infections. 
INCREASES IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL 
(LDL-C) 
Increases in LDL-C occur with DAPAGLIFLOZIN . 
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BLADDER CANCER 
             Bladder cancer risk factors and hematuria (a potential indicator of pre-
existing tumors) were balanced between treatment arms at baseline. There are 
insufficient data to determine whether DAPAGLIFLOZIN has an effect on pre-
existing bladder tumors. Consequently, DAPAGLIFLOZIN should not be used 
in patients with active bladder cancer.  
ADVERSE REACTIOS: 
The following important adverse reactions are described below and elsewhere in 
the labeling: 
 Hypotension  
 Ketoacidosis  
 Acute Kidney Injury and Impairment in Renal Function Urosepsis and 
Pyelonephritis Hypoglycemia with Concomitant Use with Insulin and 
Insulin Secretagogues  
 Genital Mycotic Infections  
 Increases in Low-Density Lipoprotein Cholesterol (LDL-C) 
 Bladder Cancer 
DRUG INTERACTIONS 
POSITIVE URINE GLUCOSE TEST 
                 Monitoring glycemic control with urine glucose tests is not 
recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase 
urinary glucose excretion and will lead to positive urine glucose tests. Use 
alternative methods to monitor glycemic control. 
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DRUG INTERACTIONS 
IN VITRO ASSESSMENT OF DRUG INTERACTIONS 
           In in vitro studies, Dapagliflozin and Dapagliflozin 3-O-glucuronide 
neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 
2B6, or 3A4. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) 
active transporter, and Dapagliflozin 3-O-glucuronide is a substrate for the 
OAT3 active transporter 
STORAGE: 
 Store DAPAGLIFLOZIN at room temperature between 68°F and 77°F 
(20°C and 25°C). 
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EMPAGLIFLOZIN58 
CHEMICAL NAME: D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-
tetrahydro-3furanyl]oxy]phenyl]methyl]phenyl]-, (1S). 
CHEMICAL FORMULA: C23H27ClO7 
STRUCURAL FORMULA: 
                          
DESCRIPTION 
               Empagliflozin, an orally-active inhibitor of the sodium-glucose co-
transporter 2 (SGLT2). The molecular weight is 450.91. 
                   Empagliflozin is a white to yellowish, non-hygroscopic powder. It is 
very slightly soluble in water, sparingly soluble in methanol, slightly soluble in 
ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically 
insoluble in toluene. 
DOSAGE FORM: Tablet 
MECHANISM OF ACTION: 
                   Sodium-glucose co-transporter 2 (SGLT2) is the predominant 
transporter responsible for reabsorption of glucose from the glomerular filtrate 
back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting 
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SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers 
the renal threshold for glucose, and thereby increases urinary glucose excretion. 
CLINICAL PHARMACOLOGY 
PHARMACODYNAMICS 
URINARY GLUCOSE EXCRETION 
                        In patients with type 2 diabetes, urinary glucose excretion 
increased immediately following a dose of EMPAGLIFLOZIN and was 
maintained at the end of a 4-week treatment period averaging at approximately 
64 grams per day with 10 mg Empagliflozin and 78 grams per day with 25 mg 
EMPAGLIFLOZIN once daily. 
URINARY VOLUME 
                     In a 5-day study, mean 24-hour urine volume increase from 
baseline was 341 mL on Day 1 and 135 mL on Day 5 of Empagliflozin 25 mg 
once daily treatment. 
PHARMACOKINETICS 
ABSORPTION 
                   The pharmacokinetics of Empagliflozin has been characterized in 
healthy volunteers and patients with type 2 diabetes and no clinically relevant 
differences were noted between the two populations. After oral administration, 
peak plasma concentrations of Empagliflozin were reached at 1.5 hours post-
dose. Thereafter, plasma concentrations declined in a biphasic manner with a 
rapid distribution phase and a relatively slow terminal phase. The steady state 
mean plasma AUC and Cmax were 1870 nmol·h/L and 259 nmol/L, 
respectively, with 10 mg Empagliflozin once daily treatment, and 4740 
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nmol·h/L and 687 nmol/L, respectively, with 25 mg Empagliflozin once daily 
treatment. Systemic exposure of Empagliflozin increased in a dose-proportional 
manner in the therapeutic dose range. The single-dose and steady-state 
pharmacokinetic parameters of Empagliflozin were similar, suggesting linear 
pharmacokinetics with respect to time. 
                    Administration of 25 mg Empagliflozin after intake of a high-fat 
and high-calorie meal resulted in slightly lower exposure; AUC decreased by 
approximately 16% and Cmax decreased by approximately 37%, compared to 
fasted condition. The observed effect of food on Empagliflozin 
pharmacokinetics was not considered clinically relevant and Empagliflozin may 
be administered with or without food. 
DISTRIBUTION 
                      The apparent steady-state volume of distribution was estimated to 
be 73.8 L based on a population pharmacokinetic analysis. Following 
administration of an oral [14C]-Empagliflozin solution to healthy subjects, the 
red blood cell partitioning was approximately 36.8% and plasma protein 
binding was 86.2%. 
METABOLISM 
                   No major metabolites of Empagliflozin were detected in human 
plasma and the most abundant metabolites were three glucuronide conjugates 
(2-O-, 3-O-, and 6-O-glucuronide).  
ELIMINATION 
                     The apparent terminal elimination half-life of Empagliflozin was 
estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the 
population pharmacokinetic analysis. Following once-daily dosing, up to 22% 
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accumulation, with respect to plasma AUC, was observed at steady-state, which 
was consistent with Empagliflozin half-life. Following administration of an oral 
[14C]-Empagliflozin solution to healthy subjects, approximately 95.6% of the 
drug-related radioactivity was eliminated in feces (41.2%) or urine (54.4%). 
The majority of drug-related radioactivity recovered in feces was unchanged 
parent drug and approximately half of drug-related radioactivity excreted in 
urine was unchanged parent drug. 
OVERDOSE 
 In the event of an overdose with EMPAGLIFLOZIN, contact the Poison 
Control Center. Employ the usual supportive measures (e.g., remove 
unabsorbed material from the gastrointestinal tract, employ clinical 
monitoring, and institute supportive treatment) as dictated by the patient's 
clinical status.  
 ROUTE OF ADMINISTRATION: oral 
DOSAGE AND ADMINISTRATION: 
RECOMENDED DOSAGE: The recommended dose of 
EMPAGLIFLOZIN is 10mg once daily in the morning, taken with or 
without food. In patient tolerating EMPAGLIFLOZIN, the dose may be 
increased to25mg. 
PATIENTS WITH RENAL IMPAIRMENT 
Assessment of renal function is recommended prior to initiation of 
EMPAGLIFLOZIN and periodically thereafter. 
EMPAGLIFLOZIN should not be initiated in patients with an eGFR less 
than 45 mL/min/1.73 m².No dose adjustment is needed in patients with an 
eGFR greater than or equal to 45 mL/min/1.73 m². 
DRUG PROFILE 
 
DEPARTMENT OF PHARMACY PRACTICE Page 86 
 
EMPAGLIFLOZIN should be discontinued if eGFR is persistently less 
than 45 mL/min/1.73 m² 
INDICATIONS 
EMPAGLIFLOZIN is indicated as an adjunct to diet and exercise to improve 
glycemic control in adults with type 2 diabetes mellitus  
EMPAGLIFLOZIN is not recommended for patients with type 1 diabetes or for 
the treatment of diabetic ketoacidosis. 
CONTRA INDICATIONS 
 History of serious hypersensitivity reaction to EMPAGLIFLOZIN. 
 Severe renal impairment, end stage renal disease or dialysis 
WARNINGS AND PRECAUTIONS 
HYPOTENSION 
                EMPAGLIFLOZIN causes intravascular volume contraction. 
Symptomatic hypotension may occur after initiating EMPAGLIFLOZIN. 
Particularly in patients with renal impairment, the elderly, in patients with low 
systolic blood pressure, and in patients on diuretics. 
                      Patients treated with EMPAGLIFLOZIN who present with signs 
and symptoms consistent with severe metabolic acidosis should be assessed for 
ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis 
associated with EMPAGLIFLOZIN may be present even if blood glucose levels 
are less than 250 mg/dL. If ketoacidosis is suspected, EMPAGLIFLOZIN 
should be discontinued, patient should be evaluated, and prompt treatment 
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should be instituted. Treatment of ketoacidosis may require insulin, fluid and 
carbohydrate replacement. 
                    In many of the postmarketing reports, and particularly in patients 
with type 1 diabetes, the presence of ketoacidosis was not immediately 
recognized and institution of treatment was delayed because presenting blood 
glucose levels were below those typically expected for diabetic ketoacidosis 
(often less than 250 mg/dL). Signs and symptoms at presentation were 
consistent with dehydration and severe metabolic acidosis and included nausea, 
vomiting, abdominal pain, generalized malaise, and shortness of breath . 
IMPAIRMENT IN RENAL FUNCTION 
                        EMPAGLIFLOZIN increases serum creatinine and decreases 
eGFR.The risk of impaired renal function with EMPAGLIFLOZIN is increased 
in elderly patients and patients with moderate renal impairment. More frequent 
monitoring of renal function is recommended in these patients . Renal function 
should be evaluated prior to initiating EMPAGLIFLOZIN and periodically 
thereafter. 
UROSEPSIS AND PYELONEPHRITIS 
                      There have been postmarketing reports of serious urinary tract 
infections including urosepsis and pyelonephritis requiring hospitalization in 
patients receiving SGLT2 inhibitors, including EMPAGLIFLOZIN. Treatment 
with SGLT2 inhibitors increases the risk for urinary tract infections. 
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HYPOGLYCEMIA WITH CONCOMITANT USE WITH INSULIN AND 
INSULIN SECRETAGOGUES 
                     Insulin and insulin secretagogues are known to cause 
hypoglycemia. The risk of hypoglycemia is increased when EMPAGLIFLOZIN 
is used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin. 
GENITAL MYCOTIC INFECTIONS 
                     EMPAGLIFLOZIN increases the risk for genital mycotic 
infections. Patients with a history of chronic or recurrent genital mycotic 
infections were more likely to develop mycotic genital infections. 
INCREASED LOW-DENSITY LIPOPROTEIN CHOLESTEROL 
                  Increases in LDL-C can occur with EMPAGLIFLOZIN. Monitor 
and treat as appropriate. 
MACROVASCULAR OUTCOMES 
                      There have been no clinical studies establishing conclusive 
evidence of macrovascular risk reduction with EMPAGLIFLOZIN or any other 
antidiabetic drug. 
ADVERSE REACTION: 
The following important adverse reactions are described below and elsewhere in 
the labeling: 
 Hypotension 
 Ketoacidosis Impairment in Renal Function 
 Urosepsis and Pyelonephritis  
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 Hypoglycemia with Concomitant Use with Insulin and Insulin 
Secretagogues 
 Genital Mycotic Infections  
 Increased Low-Density Lipoprotein Cholesterol (LDL-C)  
 
DRUG INTERACTIONS 
DIURETICS 
                Co administration of Empagliflozin with diuretics resulted in 
increased urine volume and frequency of voids, which might enhance the 
potential for volume depletion. 
INSULIN OR INSULIN SECRETAGOGUES 
                 Co administration of Empagliflozin with insulin or insulin 
secretagogues increases the risk for hypoglycemia. 
POSITIVE URINE GLUCOSE TEST 
                Monitoring glycemic control with urine glucose tests is not 
recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase 
urinary glucose excretion and will lead to positive urine glucose tests. 
STORAGE 
 Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) 
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REVIEW OF LIERATURE 
1. Cersosimo E59 et al., The importance of the kidney in glucose homeostasis 
has been recognized for many years. Recent observations indicating a greater 
role of renal glucose metabolism in various physiologic and pathologic 
conditions have rekindled the interest in renal glucose handling as a potential 
target for the treatment of diabetes. The enormous capacity of the proximal 
tubular cells to reabsorb the filtered glucose load entirely, utilizing the sodium-
glucose co-transporter systembecame the focus of attention.  Subsequently, 
several compounds with more selective SGLT-2 inhibition properties  were 
developed. . In general, a 6-month period of therapy with SGLT-2 inhibitors is 
followed by a mean urinary glucose excretion rate of ~80 g/day accompanied by 
a decline in fasting and postprandial glucose with average decreases in HgA1C 
~1.0%. Concomitant body weight loss and a mild but consistent drop in blood 
pressure also have been reported. In contrast, transient polyuria, thirst with 
dehydration and occasional hypotension have been described early in the 
treatment. In addition, a significant increase in the occurrence of uro-genital 
infections, particularly in women has been documented with the use of SGLT-2 
inhibitors. 
 
2. Singh AK60 et al.,The gradual decline in β-cell function is inevitable in type 
2 diabetes mellitus and therefore, substantial proportions of patients require 
insulin subsequently, in order to achieve optimal glucose control. While weight 
gain, hypoglycemia, and fluid retention especially during dose intensification is 
a known limitation to insulin therapy, these adverse effects also reduce patient 
satisfaction and treatment adherence. It is also possible that the benefits of 
intensive control achieved by insulin therapy, perhaps get nullified by the 
weight gain and hypoglycemia. In addition, improvement in plasma glucose or 
glycated hemoglobin (HbA1c) itself is associated with weight gain. Notably, 
studies have already suggested that reduction in body weight by ~3-5%, may 
allow a significantly better glycemic control. Thus, a class of drugs, which can 
reduce HbA1c effectively, yet are weight neutral or preferably reduce body 
weight, could be the most sought out strategy as an add-on therapy to insulin. 
While sulfonylureas (SUs) are associated with weight gain and hypoglycemia, 
pioglitazone increases body weight and fluid retention. Moreover, SUs are not 
recommended once premix or prandial insulin is commenced. The addition of 
newer agents, such as glucagon-like peptide-1 receptor agonist to insulin 
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certainly appears to be an effective tool in reducing both HbA1c and body 
weight as is evident across the studies; however, this approach incurs an 
additional injection as well as cost. Dipeptidyl peptidase-4 inhibitors (DPP-4I) 
and sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are other exciting 
options, as an add-on to insulin therapy primarily these drugs and do not possess 
any intrinsic potential of hypoglycemia. Furthermore, these are either weight 
neutral or induce significant weight loss.  
3. James F List61 et al.,Dapagliflozin, a novel inhibitor of renal sodium-glucose 
cotransporter 2, allows an insulin-independent approach to improve type 2 
diabetes hyperglycemia.Type 2 diabetic patients were randomly assigned to one 
of five dapagliflozin doses, metformin XR, or placebo for 12 weeks. The 
primary objective was to compare mean change from baseline in A1C. Other 
objectives included comparison of changes in fasting plasma glucose (FPG), 
weight, adverse events, and laboratory measurements. After 12 weeks, 
dapagliflozin induced moderate glucosuria (52-85 g urinary glucose/day) and 
demonstrated significant glycemic improvements versus placebo (DeltaA1C -
0.55 to -0.90% and DeltaFPG -16 to -31 mg/dl). Weight loss change versus 
placebo was -1.3 to -2.0 kg. There was no change in renal function. Serum uric 
acid decreased, serum magnesium increased, serum phosphate increased at 
higher doses, and dose-related 24-h urine volume and hematocrit increased,  
Treatment-emergent adverse events were similar across all groups. 
Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 
diabetic patients by inducing controlled glucosuria with urinary loss of 
approximately 200-300 kcal/day. Dapagliflozin treatment demonstrated no 
persistent, clinically significant osmolarity, volume, or renal status changes. 
4. Mudaliar S62 et al., Type 2 diabetes is a chronic disease with disabling 
micro- and macrovascular complications that lead to excessive morbidity and 
premature mortality.  Although insulin resistance and insulin secretory defects 
play a major role in the pathogenesis of hyperglycemia, metabolic defects 
contribute to the initiation/worsening of the diabetic state. Instead of an increase 
in renal glucose excretion, which could ameliorate hyperglycemia, there is an 
increase in renal glucose reabsorption, which helps sustain hyperglycemia in 
patients with diabetes. The sodium-glucose cotransporter (SGLT) 2 inhibitors 
are novel antidiabetes agents that inhibit renal glucose reabsorption and promote 
glucosuria, thereby leading to reductions in plasma glucose concentrations.  
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5.Riggs K63 et al.,The concurrent management of type 2 diabetes mellitus 
(T2DM) and chronic congestive heart failure presents several therapeutic 
challenges. insulin and insulin-sensitizing medications detrimentally "flood" the 
heart with energy-providing substrates, including fats and glucose. Sodium 
glucose cotransporter-2 (SGLT-2) inhibitors, a new class of antidiabetic 
medication, operate via this principle by blocking the reabsorption of glucose in 
the kidney and subsequently releasing glucose through the urine. the potential 
role of SGLT-2 inhibitor therapy in patients with concurrent T2DM and chronic 
heart failure. SGLT-2 inhibitors are safe and can be recommended to treat 
T2DM in patients with chronic heart failure and intact renal function. Further 
studies are in progress to assess long-term survival benefits. 
6. Halimi S64 et al., In type 2 diabetes (T2DM), glycaemic control delays the 
development and slows the progression of complications. Although there are 
numerous glucose-lowering agents in clinical use, only approximately half of 
T2DM patients achieve glycaemic control. Sodium-glucose cotransporter-2 
inhibitors (SGLT-2-i) have recently been developed for the treatment of T2DM. 
The available data suggest a good tolerability profile for the three available 
drugs - canagliflozin, dapagliflozin and empagliflozin - approved by the US 
Food and Drug Administration (FDA) for the American market as well as in 
other countries. The most frequently reported adverse events with SGLT-2 are 
female genital mycotic infections, urinary tract infections and increased 
urination. The pharmacodynamic response to SGLT-2-i declines with increasing 
severity of renal impairment, requiring dosage adjustments or restrictions with 
moderate-to-severe renal dysfunction. Most patients treated with SGLT-2 also 
have a modest reduction in blood pressure and modest effects on serum lipid 
profiles, some of which are beneficial .In patients treated with dapagliflozin, a 
non-significant excess number of breast and bladder cancers has been reported;   
Although there is some benefit for several cardiovascular risk factors such as 
HbA1c, high blood pressure, obesity and increases in LDL-C, adequately 
powered trials are still required to determine the effects of SGLT-2 on 
macrovascular outcomes. 
7. Storgaard H65  et al., Sodium-glucose co-transporter 2 inhibitors (SGLT-2) 
increase urinary glucose excretion through a reduced renal glucose reabsorption.   
meta-analyses of randomised clinical trials on SGLT-2 versus placebo, other 
oral glucose lowering drugs or insulin for patients with type 2 diabetes will be 
performed. The primary end point will be the glycated haemoglobin. Secondary 
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end points will include changes in body weight, body mass index, fasting 
plasma glucose, plasma cholesterol, kidney and liver blood tests, blood pressure 
and adverse events. Electronic and manual searches will be performed. Meta-
analyses will be performed and the results presented as mean differences for 
continuous outcomes and risk differences for dichotomous outcomes, both with 
95% CIs. Subgroup, sensitivity, regression and sequential analyses will be 
performed to evaluate inter trial heterogeneity, bias and the robustness of results 
due to cumulative testing. 
8. Schnell O66 et al.,The role for the novel treatment approach of sodium-
glucose cotransporter-2 (SGLT-2) in type 2 diabetes is increasing. Structured 
self-monitoring of blood glucose (SMBG), based on a less intensive and a more 
intensive scheme, may contribute to an optimization of SGLT-2 inhibitor based 
treatment. The expert recommendation suggests individualized approaches of 
SMBG, using simple and clinically applicable schemes. Potential benefits of 
SMBG in SGLT-2 inhibitor based treatment approaches are early assessment of 
treatment success or failure, timely modification of treatment, detection of 
hypoglycemic episodes, assessment of glucose excursions, and support of 
diabetes management and education. The length and frequency of SMBG 
should depend on the clinical setting and the quality of metabolic control 
9.Tahrani AA67 et al.,The two main sodium-glucose cotransporters (SGLTs), 
SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia 
in patients with diabetes. SGLT1 enables the small intestine to absorb glucose 
and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is 
responsible for reabsorption of most of the glucose filtered by the kidney. 
Inhibitors with varying specificities for these transporters (eg, dapagliflozin, 
canagliflozin, and empagliflozin) can slow the rate of intestinal glucose 
absorption and increase the renal elimination of glucose into the urine. Results 
of randomised clinical trials have shown the blood glucose-lowering efficacy of 
SGLT inhibitors in type 2 diabetes when administered as monotherapy or in 
addition to other glucose-lowering therapies including insulin. Increased renal 
glucose elimination also assists weight loss and could help to reduce blood 
pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and 
might increase risk of urinary tract and genital infection, and excessive 
inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the 
insulin-independent mechanism of action of SGLT inhibitors seems to offer 
durable glucose-lowering efficacy with low risk of clinically significant 
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hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT 
inhibition might also be considered in conjunction with insulin therapy in type 1 
diabetes. 
10.Singh AK68 et al., As type 2 diabetes mellitus (T2DM) is a chronic and 
progressive disease with multiple pathophysiologic defects, no single anti-
diabetic agent can tackle all these multi-factorial pathways. Consequently, 
multiple agents working through the different mechanisms will be required for 
the optimal glycemic control. Moreover, the combination therapies of different 
anti-diabetic agents may complement their actions and possibly act synergistic.  
Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are newly emerging 
class of drugs, with a great potential to reduce glucose effectively with an 
additional quality of lowering cardiovascular events  However, increase in 
endogenous glucose production (EGP) from the liver, either due to the increase 
in glucagon or compensatory response to glucosuria can offset the glucose-
lowering potential of SGLT-2I. Interestingly, another class of drugs such as 
dipeptidyl peptidase-4 inhibitors (DPP-4I) effectively decrease glucagon and 
reduce EGP. In light of these findings, combination therapies with SGLT-2I and 
DPP-4I are particularly appealing and are expected to produce a synergistic 
effect. Preclinical studies of combination therapies with DPP-4I and SGLT-2I 
have already demonstrated a significant lowering of hemoglobin A1c potential 
and human studies also find no drug-drug interaction between these agents. 
 
11.Rosenwasser RF69 et al., sodium glucose co-transporter 2 (SGLT-2) 
inhibitors  lower glucose by enhancing its excretion by blocking reabsorption in 
the renal tubules, thus eliminating glucose from the body along with the 
molecules' attendant effects on caloric balance, plasma osmolality, and lipids. 
Consequently, SGLT-2 inhibitors improve glucose control to an extent 
comparable to other hypoglycemic agents while simultaneously reducing body 
weight, blood pressure, and cholesterol . One agent, canagliflozin, has recently 
been approved by the US Food and Drug Administration (FDA) and two other 
agents have progressed through Phase III trials, including dapagliflozin and 
empagliflozin. Collectively, when used as monotherapy, these agents have 
demonstrated reductions in hemoglobin A1c (HbA1c), body weight, and blood 
pressure of -0.34% to -1.03%, -2.0 to -3.4 kg, and -1.7 to -6.4 mmHg/-0.3 to -
2.6 mmHg (systolic blood pressure/diastolic blood pressure), respectively. 
SGLT-2 inhibitors have been well tolerated, with hypoglycemia (0.9% to 4.3%) 
occurring infrequently in clinical trials. Safety signals related to breast and 
bladder cancer have arisen with dapagliflozin. As these agents emerge, 
clinicians should embrace the addition to the formulary for treating type 2 
diabetes, but must also weight the risk-benefit of this new class in deciding 
which patient types are most likely to benefit from their novel mechanism of 
action. 
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12. Albarrán OG70 et al.,Dapagliflozin is the first novel sodium-glucose co-
transporter-2 (SGLT2) inhibitor approved by the European Medicines Agency 
(EMA) for the treatment of type 2 diabetes. By inhibiting SGLT2, dapagliflozin 
blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose 
excretion and reducing blood glucose levels. Its mechanism of action is 
independent of pancreatic β cell function and modulation of insulin sensitivity. 
The results of phase III clinical trials showed that dapagliflozin, at a dose of 5 or 
10mg/day for 24 weeks as monotherapy in previously untreated patients, or as 
add-on combination therapy with metformin, glimepiride, pioglitazone or 
insulin-based therapy, significantly reduced both HbA1c and fasting plasma 
glucose levels compared with placebo. In addition, dapagliflozin was 
noninferior to glipizide, in terms of glycemic control after 52 weeks, when used 
as add-on therapy in patients with type 2 diabetes inadequately controlled with 
metformin. In most clinical trials, dapagliflozin reduced body weight. The 
combination of both effects (improved glycemic control and weight loss) is 
achieved to a greater extent in treatments that include dapaglifozin. Longer-term 
extension studies indicated that the efficacy of dapagliflozin on the glycemic 
control and weight reductión is maintained for up to 2 and 4 years. 
Dapagliflozin was well tolerated. Genital infections and urinary tract infections 
were more frequent in patients who received dapagliflozin than in placebo 
recipients. Hypoglycemic episodes were scarce with dapagliflozin. In 
conclusion, dapagliflozin is a novel option for the management of type 2 
diabetes, particularly when used as add-on therapy. 
 
13.Zhang Q71 et  al.,In search of add-on treatments to metformin, sodium-
glucose cotransporter-2 (SGLT-2) inhibitors are potential candidates. This 
meta-analysis examines the potential use of SGLT-2 inhibitors in combination 
with metformin as a therapeutic option for type 2 diabetes management in 
patients with inadequate control with metformin.A literature search was made in 
several databases for randomized controlled trials (RCTs) utilizing metformin 
therapy combined with SGLT-2 inhibitors or placebo. Heterogeneity was 
estimated with I(2) statistics and random effect model was chosen for the meta-
analyses of mean differences in changes from baseline in both SGLT-2 inhibitor 
treated and control groups Seven RCTs were selected for the meta-analysis. In 
comparison with placebo-MET, the SGLT-2 inhibitor-MET combination 
therapy resulted in significant HbA1c decline in 12-24 week duration, to less 
REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACY PRACTICE Page 96 
 
extent after 1 year (-0.37 [-0.77, 0.03]; P=0.07) but not by 2 year (-0.41 [-1.09, 
0.28]; P=0.24) duration. SGLT-2 inhibitor-MET significantly lowered FPG and 
body weight after 24 weeks, 1 year, and 2 years. Systolic and diastolic blood 
pressure declined only in the short-term (12-24 weeks). After 2 years, neither 
systolic (-1.80 [-6.18, 2.58]; P=0.42) nor diastolic blood pressure (-0.20 [-2.94, 
2.54]; P=0.89) declined significantly more than control. Incidence of suspected 
genital infections was slightly more in SGLT-2 inhibitor-MET group. 
14.Gilbert RE72 et al., With the advent of sodium-glucose linked transporter-2 
(SGLT-2) inhibitors, physicians are now aware that the kidney also needs to be 
considered in the spectrum of action of anti-hyperglycaemic agents. Though 
familiar with the need for dose adjustment when prescribing many of our 
current anti-hyperglycaemic drugs in the setting of kidney dysfunction, with the 
SGLT-2 inhibitors pharmacodynamic as well as pharmacokinetic aspects also 
need to be considered. Finally, through their ability to reduce intraglomerular 
pressure, systemic blood pressure and plasma uric acid concentration, the 
SGLT-2 inhibitors offers the possibility of kidney protection. An hypothesis 
that will need to be tested with long term studies that address changes in the 
kidney beyond albuminuria, assessing the rate of decline in glomerular filtration 
rate and 'hard' kidney related endpoints such as the need for renal replacement 
therapy (dialysis, transplantation) will be important in this setting. 
15.Gallo LA73 et al., Traditional treatments for type 1 and type 2 diabetes are 
often associated with side effects, including weight gain and hypoglycaemia 
that may offset the benefits of blood glucose lowering. The kidneys filter and 
reabsorb large amounts of glucose, and urine is almost free of glucose in normo 
glycemia. The sodium-dependent glucose transporter (SGLT)-2 in the early 
proximal tubule reabsorbs the majority of filtered glucose. Remaining glucose is 
reabsorbed by SGLT1 in the late proximal tubule. Diabetes enhances renal 
glucose reabsorption by increasing the tubular glucose load and the expression 
of SGLT2, which maintains hyperglycaemia. Inhibitors of SGLT2 enhance 
urinary glucose excretion and thereby lower blood glucose levels in type 1 and 
type 2 diabetes. The load-dependent increase in SGLT1-mediated glucose 
reabsorption explains why SGLT2 inhibitors in normoglycaemic conditions 
enhance urinary glucose excretion to only ~50% of the filtered glucose. The role 
of SGLT1 in both renal and intestinal glucose reabsorption provides a rationale 
for the development of dual SGLT1/2 inhibitors. SGLT2 inhibitors lower blood 
glucose levels independent of insulin and induce pleiotropic actions that may be 
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relevant in the context of lowering cardiovascular risk. Ongoing long-term 
clinical studies will determine whether SGLT2 inhibitors have a safety profile 
and exert cardiovascular benefits that are superior to traditional agents. 
16.Zanoli L74 et al.,SGLT2 inhibitors are new antihyperglycaemic agents 
whose ability to lower glucose is directly proportional to GFR. Therefore, in 
chronic kidney disease (CKD) the blood glucose lowering effect is reduced. 
Unlike many current therapies, the mechanism of action of SGLT2 inhibitors is 
independent of insulin action or beta-cell function. In addition, the mechanism 
of action of SGLT2 inhibitors is complementary and not alternative to other 
antidiabetic agents. SGLT2 inhibitors could be potentially effective in 
attenuating renal hyperfiltration and, consequently, the progression of CKD. 
Moreover, the reductions in intraglomerular pressure, systemic blood pressure, 
and uric acid levels induced by SGLT inhibition may potentially be of benefit in 
CKD subjects without diabetes. However, at present, only few clinical studies 
were designed to evaluate the effects of SGLT2 inhibitors in CKD. 
Consequently, safety and potential efficacy beyond blood glucose lowering 
should be better clarified in CKD. 
17.Marques AR75 et al.,Who never had a type 2 obese diabetic patient, treated 
by several oral antidiabetic drugs and insulin, with consequent weight gain 
associated with the therapeutic escalation and uncontrolled diabetes The arrival 
of GLP-1 agonists and SGLT-2 inhibitors allows to reevaluate the management 
of these patients, with their favorable effects on glycemic control, weight and 
the risk of hypoglycemia and their complementary mechanisms to conventional 
treatments. The vicious cycle of weight gain and increased need of insulin is 
limited. The choice between these two molecules must be based on several 
factors (glycemic target, weight, comorbidities, route of administration, side 
effects, etc.), and the balanced enthusiasm of these new treatments with the 
insufficient data regarding their long-term safety and their impact on micro- and 
macrovascular complications 
18. Goring S76 et al., Indirect evidence from randomized controlled trials 
(RCTs) was used to estimate the effect of dapagliflozin, a new agent with a 
novel mechanism of action (SGLT-2 inhibition), relative to other anti-diabetes 
therapies after 1 year of treatment. RCTs enrolling subjects with type 2 diabetes 
inadequately controlled on metformin monotherapy were included. Comparators 
included dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), 
sulphonylureas, glucagon-like peptide-1 (GLP-1) analogues and dapagliflozin. 
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Outcomes of interest were mean change from baseline HbA1c, weight and 
systolic blood pressure, and incidence of hypoglycaemia. From 4270 abstracts, 
six RCTs were included in the primary analysis; no RCTs involving GLP-1 
analogues met primary inclusion criteria. All RCTs were actively controlled 
with sulphonylureas. The mean change in HbA1c from baseline was similar 
across comparators. The treatment effect (95% credible interval) of 
dapagliflozin on HbA1c was -0.08% (-0.25, 0.10) relative to DPP-4 inhibitors, -
0.02% (-0.24, 0.21) relative to TZDs and 0.00% (-0.16, 0.16) relative to 
sulphonylureas. Non-sulphonylureas showed significantly lower risk of 
hypoglycaemia relative to sulphonylureas. Dapagliflozin had a significant effect 
on weight change: the relative difference was -2.74 kg (-5.35, -0.10) compared 
with DPP-4 inhibitors, and -4.67 kg (-7.03, -2.35) compared with 
sulphonylureas.  
19. Kleefstra N77 et al., To describe the efficacy and safety of dapagliflozin, the 
first sodium-glucose co-transporter-2 (SGLT-2) inhibitor for the treatment of 
diabetes mellitus type 2 (DM2) to be registered in the Netherlands. We searched 
the Medline database for articles on the use of dapagliflozin in patients with 
DM2. We included randomised studies with a minimum duration of 12 weeks 
and systematic reviews published up to 19 October 2012. Two assessors 
selected the articles on the basis of title, abstract and if necessary, the complete 
text.Eleven articles were suitable for analysis. On comparison with placebo, the 
use of dapagliflozin gave a drop in HbA1c-value of approximately 0.5-0.8 
percentage points (6-9 mmol/mol). The body weight of patients who used 
dapagliflozin dropped between 1.0-2.4 kg on comparison with the placebo and 
metformin control groups. Urinary tract infections occurred twice as often and 
genital infections three to four times more often. There were no data on the 
effect on micro- and macrovascular complications or on mortality. 
20.Rudofsky G78 et al.,Since end of 2012 a new therapeutical approach for the 
treatment of type 2 diabetes is available in Germany. It relies on the modulation 
of glucose re-absorption in the kidney by inhibition of so called Sodium 
Glucose Linked Transporters (SGLT) thereby leading to therapeutical 
glucosuria. Putting the kidney in the centre of therapeutical approach of glucose 
regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the 
underlying renal mechanisms and to present the advantages and disadvantages 
of this new therapeutic class. 
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21.Bhartia M79 et al.,The prevalence of type 2 diabetes is increasing 
worldwide. The majority of currently available glucose-lowering agents work 
via insulin-dependent mechanisms and have significant limitations. Hence, there 
is a need for newer treatments utilizing novel therapeutic targets. Drugs which 
inhibit the sodium glucose cotransporter in the renal tubules (SGLT-2 
inhibitors), represent a novel class of drugs under development. By inhibiting 
SGLT-2, they promote increased renal glucose excretion and thereby calorie 
loss with improved glycemic control and weight loss. Dapagliflozin is most 
advanced in development of this new drug class and currently undergoing phase 
3 trials. In addition to its glucose lowering effect, dapagliflozin appears to have 
favorable impacts on weight and blood pressure, with low risk of hypoglycemia. 
However, as with all new treatments, long-term safety is an issue. Clinical trials 
showed increased risk of genital and possibly urinary infections with 
dapgliflozin. Furthermore, concerns have arisen regarding a possible increased 
incidence of breast and bladder cancer in patients on dapagliflozin.  
22.Abdul-Ghani MA80 et al.,Hyperglycemia plays an important role in the 
pathogenesis of type 2 diabetes mellitus, i.e., glucotoxicity, and it also is the 
major risk factor for microvascular complications. Thus, effective glycemic 
control will not only reduce the incidence of microvascular complications but 
also correct some of the metabolic abnormalities that contribute to the 
progression of the disease. Achieving durable tight glycemic control is 
challenging because of progressive β-cell failure and is hampered by increased 
frequency of side effects, e.g., hypoglycemia and weight gain. Most recently, 
inhibitors of the renal sodium-glucose cotransporter have been developed to 
produce glucosuria and reduce the plasma glucose concentration. These oral 
antidiabetic agents have the potential to improve glycemic control while 
avoiding hypoglycemia, to correct the glucotoxicity, and to promote weight 
loss. In this review, we will summarize the available data concerning the 
mechanism of action, efficacy, and safety of this novel antidiabetic therapeutic 
approach. 
23.Kinne RK81 et al.,Recently, the idea has been developed to lower blood 
glucose blood glucose levels in diabetes by inhibiting sugar reabsorption sugar 
reabsorption in the kidney . The main target is thereby the early proximal tubule  
secondary active transport of the sugar is mediated by the sodium-D: -glucose 
D-glucose cotransporter SGLT2 SGLT2 . A model substance for the inhibitors 
inhibitors is the O-glucoside O-glucoside phlorizin phlorizin which inhibits 
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transport transport competitively. Its binding to the transporter involves at least 
two different domains: aglycone binding site at the transporter surface, 
involving extramembranous loops sugar binding /translocation site buried in a 
hydrophilic pocket of the transporter. The properties of these binding sites differ 
between SGLT2 and SGLT1 SGLT1 , which mediates sugar absorption  in the 
intestine  Various O-, C-, N- and S-glucosides have been synthesized with high 
affinity  and high specificity  for SGLT2 . Some of these glycosides are in 
clinical trials  and have been proven to successfully increase urinary glucose 
excretion and to decrease blood sugar levels without the danger of 
hypoglycaemia  during fasting in type 2 diabetes . 
24. Washburn WN82 et al.,A critical factor for maintenance of glucose balance 
is the renal recovery of glucose from the glomerular filtrate mediated primarily 
by sodium glucose co-transporter 2 (SGLT2). This capacity can be modulated 
by SGLT2 inhibitors thereby providing a unique insulin independent method of 
treatment of diabetes.These compounds comprise O, C and N-glycosides 
generated by attachment of an appropriate lipophilic aglycone component to a 
suitable glucose analogue.The realization that the in vivo potency of O-
glucosides was markedly less than that of C-glucosides necessitated a shift in 
medicinal chemistry focus of the pharmaceutical companies pursuing SGLT2 
inhibitors. The role of SGLT2 inhibitors for treatment of diabetes will be 
established by the outcome of the five compounds in advanced clinical trials. 
25.Wan HX83 et al.,Sodium-glucose co-transporters are a family of glucose 
transporter found in the intestinal mucosa of the small intestine (SGLT-2) and 
the proximal tubule of the nephron (SGLT-1 and SGLT-2). They contribute to 
renal glucose reabsorption and most of renal glucose (about 90%) is reabsorbed 
by SGLT-2 located in the proximal renal tubule. Selectively inhibiting activity 
of SGLT-2 is an innovative therapeutic strategy for treatment of type 2 diabetes 
by enhancing urinary glucose excretion from the body. Therefore SGLT-2 
inhibitors are considered to be potential antidiabetic drugs with an unique 
mechanism. This review will highlight some recent advances and structure-
activity relationships in the discovery and development of SGLT-2 inhibitors 
including O-glycoside, C-glycoside, C, O-spiro glycoside and non glycosides. 
26. Imprialos KP84 et al.,Diabetes mellitus is a major issue of public health, 
affecting more than 300 million people worldwide. Inhibitors of the sodium-
glucose cotransporter-2 (SGLT-2) in the renal proximal tubule are a novel class 
of agents for the treatment of type 2 diabetes mellitus. Inhibition of the SGLT-2 
REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACY PRACTICE Page 101 
 
results in reduced glucose reabsorption and improvement in glycemic control. 
Alongside glucose excretion, SGLT-2 inhibitors also have mild natriuretic and 
diuretic effects, combining actions of a proximal tubule diuretic and an osmotic 
diuretic; these properties are expected to lead to small blood pressure (BP) 
reductions. Clinical studies with dapagliflozin, canagliflozin, empagliflozin, 
ipragliflozin, luseogliflozin, and tofogliflozin used either as monotherapy or 
add-on therapy and compared with placebo or active treatment have also 
examined the effect of these agents on BP as a secondary endpoint. Although 
with some differences between individual agents, all of the approved SGLT-2 
inhibitors provided a mild but meaningful reduction in  SBP and DBP. Recent 
studies with the use of ambulatory blood pressure monitoring suggest that the 
magnitude of this BP reduction can be even greater.  
27.Lucio R. Volino85 et al.,Diabetes mellitus continues to be a major health 
issue worldwide. Despite all of the treatment options available on the market, 
many patients with diabetes fail to reach their treatment goals. Novel agents 
such as the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors show promise 
in effectively lowering blood glucose. Objective: To review the scientific 
literature for efficacy information regarding the use of approved SGLT2 
inhibitors (canagliflozin, dapagliflozin and empagliflozin) in the treatment of 
Type 2 Diabetes Mellitus (T2DM). Methods: A MEDLINE (1950-August 2014) 
literature review was performed. All of the literature published as an original 
clinical trial was included in this review. Conclusions: With an increasing 
prevalence and incidence of type 2 diabetes mellitus worldwide, there is an 
apparent need for effective therapeutic strategies to combat this chronic and 
progressive disease. SGLT2 inhibitors offer this potential. Recently approved 
agents (canagliflozin, dapagliflozin and empagliflozin) have shown significant 
promise as mono- and add-on therapy to current glucose-lowering regimens that 
may not otherwise be providing sufficient glycemic control in T2DM patients. 
28. A.J. Scheen86 et al.,Sodium-glucose cotransporter type 2 (SGLT-2) 
inhibitors (canagliflozin, dapagliflozin, empagliflozin) are new glucose-
lowering agents that exert their therapeutic activity independently of insulin by 
facilitating glucose excretion through the kidneys. However, this simple renal 
mechanism that results in sustained glucose urinary loss leads to more complex 
indirect metabolic effects. First, by reduction of chronic hyperglycaemia and 
attenuation of glucose toxicity, SGLT-2 inhibitors can improve both insulin 
secretion by beta cells and peripheral tissue insulin sensitivity. In the case of 
canagliflozin, because of low-potency SGLT1 inhibition, a non-renal (intestinal) 
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effect may also be considered, which may contribute to better control of 
postprandial hyperglycaemia, although this contribution remains to be better 
analyzed in humans. Second, chronic glucose loss most probably leads to 
compensatory mechanisms. One of them, although not well evidenced in 
humans, might involve an increase in energy intake, an effect that may limit 
weight loss in the long run. Another could be an increase in endogenous glucose 
production, most probably driven by increased glucagon secretion, which may 
somewhat attenuate the glucose lowering effect. Nevertheless, despite these 
compensatory mechanisms and most probably because of the positive effects of 
the reduction in glucotoxicity, SGLT-2 inhibitors exert clinically relevant 
glucose-lowering activity while promoting weight loss, a unique dual effect 
among oral antidiabetic agents. Furthermore, the combination of SGLT-2 
inhibitors with other drugs that either have anorectic effects (such as incretin-
based therapies) or reduce hepatic glucose output (like metformin) and, thus, 
may dampen these two compensatory mechanisms appears appealing for the 
management of type 2 diabetes mellitus. 
29. Muhammad A Abdul-Ghani87 et al.,Hyperglycemia plays an important 
role in the pathogenesis of type 2 diabetes mellitus, i.e., glucotoxicity, and it 
also is the major risk factor for microvascular complications. Thus, effective 
glycemic control will not only reduce the incidence of microvascular 
complications but also correct some of the metabolic abnormalities that 
contribute to the progression of the disease. Achieving durable tight glycemic 
control is challenging because of progressive β-cell failure and is hampered by 
increased frequency of side effects, e.g., hypoglycemia and weight gain. Most 
recently, inhibitors of the renal sodium-glucose cotransporter have been 
developed to produce glycosuria and reduce the plasma glucose concentration. 
These oral antidiabetic agents have the potential to improve glycemic control 
while avoiding hypoglycemia, to correct the glucotoxicity, and to promote 
weight loss.  
30. Singh AK88 et  al.,Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) 
are newly approved class of oral anti-diabetic drugs, in the treatment of type 2 
diabetes, which reduces blood glucose through glucouresis via the kidney, 
independent, and irrespective of available pancreatic beta-cells. Studies 
conducted across their clinical development program found, a modest reduction 
in glycated hemoglobin ranging from -0.5 to -0.8%, without any significant 
hypoglycemia. Moreover, head-to-head studies versus active comparators 
yielded comparable efficacy. Interestingly, weight and blood pressure reduction 
were additionally observed, which was not only consistent but significantly 
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superior to active comparators, including metformin, sulfonylureas, and 
dipeptydylpeptide-4 inhibitors. Indeed, these additional properties makes this 
class a promising oral anti-diabetic drug. Surprisingly, a potentially fatal 
unwanted side effect of diabetic ketoacidosis has been noted with its widespread 
use.  
31. Andrew Ahmann89 et al.,Type 2 diabetes mellitus (T2DM) management is 
complex, with few patients successfully achieving recommended glycemic 
targets with monotherapy, most progressing to combination therapy, and many 
eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) 
inhibitors are an emerging class of antidiabetes agents with an insulin-
independent mechanism of action, making them suitable for use in combination 
with any other class of antidiabetes agents, including insulin. This review 
evaluates a 78-week, randomized, double-blind, placebo-controlled trial 
investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to 
basal insulin in patients with inadequate glycemic control on basal insulin, with 
or without metformin and/or a sulfonylurea. Empagliflozin added on to basal 
insulin resulted in significant and sustained reductions in glycated hemoglobin 
(HbA1c) levels compared with placebo. Empagliflozin has previously been 
shown to induce weight loss, and was associated with sustained weight loss in 
this study. This combination therapy was well tolerated, with similar levels of 
hypoglycemic adverse events in the empagliflozin and placebo groups over the 
78-week treatment period. Urinary tract infections and genital infections, side 
effects associated with SGLT2 inhibitors, were reported more commonly in the 
empagliflozin group; however, such events led to treatment discontinuation in 
very few patients. These findings suggest that, with their complementary 
mechanisms of action, empagliflozin added on to basal insulin may be a useful 
treatment option in patients on basal insulin who need additional glycemic 
control without weight gain. 
32. William L Baker89 et al., Sodium-glucose co-transporter 2 (SGLT2) 
inhibitors represent a new class of antihyperglycemic agents that block renal 
sodium and glucose reabsorption and may reduce blood pressure (BP). We 
assessed the BP lowering ability of these agents using meta-analytic techniques.  
We included fully published randomized controlled trials (RCTs) that evaluated 
SGLT2 inhibitors in patients with type-2 diabetes mellitus and reported change 
in systolic and/or diastolic BP. Subgroup analyses were performed for placebo-
controlled trials and those with active controls. We also conducted meta-
regression to assess for a dose-response effect, and whether baseline BP, 
changes in body weight, heart rate, and hematocrit were associated with the BP 
effects. Results Twenty seven RCTs (n=12,960 participants) were included. 
SGLT2 inhibitors significantly reduced both SBP (weighted mean difference 
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[WMD] -4.0 mmHg, 95% CI -4.4 to -3.5) and DBP (WMD -1.6 mmHg, 95% CI 
-1.9 to -1.3) from baseline. Only canagliflozin had a significant dose-response 
relationship with SBP (p=0.008). Significant reductions in body weight and 
hematocrit were seen with the SGLTs. SGLTs had no significant effect on the 
incidence of orthostatic hypotension (p>0.05).  Sodium-glucose co-transporter 2 
inhibitors significantly reduce BP in patients with type 2 diabetes. 
33.Anna Solini90 et al.,In the last ten years, knowledge on pathophysiology of 
type 2 diabetes (T2DM) has significantly increased, with multiple failures 
(decreased incretin effect, increased lipolysis, increased glucagon secretion, 
neurotransmitters dysfunction) recognized as important contributors, together 
with decreased insulin secretion and reduced peripheral glucose uptake. As a 
consequence, the pharmacologic therapy of T2DM has been progressively 
enriched by several novel classes of drugs, trying to overcome these defects.  
SGLT2 inhibitors, framing the kidney in a different scenario, not as site of a 
harmful disease complication, but rather as the means to correct hyperglycemia 
and fight the disease. This review aims to offer a short, updated overview of the 
role of these compounds in the treatment of T2DM, focusing on efficacy, 
ancillary albeit relevant clinical effects, safety, potential cardiovascular 
protection, positioning in common therapeutic algorithms. 
34.Aurora Merovci91 et al., β-Cell dysfunction is a core defect in T2DM, and 
chronic, sustained hyperglycemia has been implicated in progressive β-cell 
failure, ie, glucotoxicity. The aim of the present study was to examine the effect 
of lowering the plasma glucose concentration with dapagliflozin, a glucosuric 
agent, on β-cell function in T2DM individuals. Research design and methods: 
Twenty-four subjects with T2DM received dapagliflozin (n = 16) or placebo (n 
= 8) for 2 weeks, and a 75-g oral glucose tolerance test (OGTT) and insulin 
clamp were performed before and after treatment. Plasma glucose, insulin, and 
C-peptide concentrations were measured during the OGTT. Results: 
Dapagliflozin significantly lowered both the fasting and 2-hour plasma glucose 
concentrations and the incremental area under the plasma glucose concentration 
curve (ΔG0-120) during OGTT by -33 ± 5 mg/dL, -73 ± 9 mg/dL, and -60 ± 12 
mg/dL · min, respectively, compared to -13 ± 9, -33 ± 13, and -18 ± 9 
reductions in placebo-treated subjects (both P < .01). The incremental area 
under the plasma C-peptide concentration curve tended to increase in 
dapagliflozin-treated subjects, whereas it did not change in placebo-treated 
subjects. Thus, ΔC-Pep0-120/ΔG0-120 increased significantly in dapagliflozin-
treated subjects, whereas it did not change in placebo-treated subjects (0.019 ± 
0.005 vs 0.002 ± 0.006; P < .01). Dapagliflozin significantly improved whole-
body insulin sensitivity (insulin clamp). Thus, β-cell function, measured as ΔC-
Pep0-120/ ΔG0-120 ÷ insulin resistance, increased by 2-fold (P < .01) in 
dapagliflozin-treated vs placebo-treated subjects. Lowering the plasma glucose 
REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACY PRACTICE Page 105 
 
concentration with dapagliflozin markedly improves β-cell function, providing 
strong support in man for the glucotoxic effect of hyperglycemia on β-cell 
function. 
35. Krzysztof Strojek92 et al., Progressive deterioration of glycaemic control in 
type 2 diabetes mellitus (T2DM) often requires treatment intensification. 
Dapagliflozin increases urinary glucose excretion by selective inhibition of 
renal sodium-glucose co transporter 2 (SGLT2). We assessed the efficacy, 
safety and tolerability of dapagliflozin added to glimepiride in patients with 
uncontrolled T2DM. This 24-week, randomized, double-blind, placebo-
controlled, parallel-group, international, multicentre trial enrolled patients with 
uncontrolled T2DM [haemoglobin A1c (HbA1c) 7-10%] receiving sulphonyl 
urea mono therapy. Adult patients (n = 597) were randomly assigned to placebo 
or dapagliflozin (2.5, 5 or 10 mg/day) added to open-label glimepiride 4 mg/day 
for 24 weeks. Primary endpoint was HbA1c mean change from baseline at 24 
weeks. Secondary endpoints included change in body weight and other 
glycaemic parameters. At 24 weeks, HbA1c adjusted mean changes from 
baseline for placebo versus dapagliflozin 2.5/5/10 mg groups were -0.13 versus 
-0.58, -0.63, -0.82%, respectively (all p < 0.0001 vs. placebo by Dunnett's 
procedure). Corresponding body weight and fasting plasma glucose values were 
-0.72, -1.18, -1.56, -2.26 kg and -0.11, -0.93, -1.18, -1.58 mmol/l, respectively. 
In placebo versus dapagliflozin groups, serious adverse events were 4.8 versus 
6.0-7.1%; hypoglycaemic events 4.8 versus 7.1-7.9%; events suggestive of 
genital infection 0.7 versus 3.9-6.6%; and events suggestive of urinary tract 
infection 6.2 versus 3.9-6.9%. No kidney infections were reported. 
Dapagliflozin added to glimepiride in patients with T2DM uncontrolled on 
sulphonylurea monotherapy significantly improved HbA1c, reduced weight and 
was generally well tolerated, although events suggestive of genital infections 
were reported more often in patients receiving dapagliflozin. 
36. B Haaset93 et al.,  Renal sodium-linked glucose transporter 2 inhibitors are 
new antidiabetic drugs with an insulin-independent mechanism of action. They 
pose one remarkable advantage compared with already established 
antidiabetics: increasing urinary glucose excretion without inducing 
hypoglycaemia, thereby promoting body weight reduction due to loss of 
~300 kcal per day. This review focuses on canagliflozin, which was the first 
successful compound of this class to be approved by both the US Food and 
Drug Administration and the European Medicines Agency in 2013. Clinical 
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trials showed promising results: enhancing glycaemic control was paralleled by 
reducing body weight and systolic and diastolic blood pressure. Nevertheless, 
some safety concerns remain, such as genital mycotic infections, urinary tract 
infections and cardiovascular risks in vulnerable patients, which will be closely 
monitored in several post-authorization safety studies. 
37.David Polidori94 et al.,In rodent models of diabetes, treatment with sodium 
glucose co-transporter 2 (SGLT2) inhibitors improves beta cell function. This 
analysis assessed the effects of the SGLT2 inhibitor, canagliflozin, on model-
based measures of beta cell function in patients with type 2 diabetes. Data from 
three Phase 3 studies were analysed, in which: (Study 1) canagliflozin 100 and 
300 mg were compared with placebo as monotherapy for 26 weeks; (Study 2) 
canagliflozin 100 and 300 mg were compared with placebo as add-on to 
metformin + sulfonylurea for 26 weeks; or (Study 3) canagliflozin 300 mg was 
compared with sitagliptin 100 mg as add-on to metformin + sulfonylurea for 52 
weeks. In each study, a subset of patients was given mixed-meal tolerance tests 
at baseline and study endpoint, and model-based beta cell function parameters 
were calculated from plasma glucose and C-peptide. In Studies 1 and 2, both 
canagliflozin doses increased beta cell glucose sensitivity compared with 
placebo. Placebo-subtracted least squares mean (LSM) (SEM) changes were 23 
(9) and 18 (9) pmol min(-1) m(-2) (mmol/l)(-1) with canagliflozin 100 and 300 
mg, respectively (p < 0.002, Study 1), and 16 (8) and 10 (9) pmol min(-1) m(-2) 
(mmol/l)(-1) (p < 0.02, Study 2). In Study 3, beta cell glucose sensitivity was 
minimally affected, but the insulin secretion rate at 9 mmol/l glucose increased 
to similar degrees from baseline with canagliflozin and sitagliptin [LSM (SEM) 
changes 38 (8) and 28 (9) pmol min(-1) m(-2), respectively; p < 0.05 for both].   
38. Robert R Henry95 et al.,This randomized, double-blind, placebo-controlled 
parallel-group study assessed the effects of sodium glucose cotransporter 2 
inhibition by dapagliflozin on insulin sensitivity and secretion in subjects with 
type 2 diabetes mellitus (T2DM), who had inadequate glycemic control with 
metformin Forty-four subjects were randomized to receive dapagliflozin 5 mg 
or matching placebo once daily for 12 weeks. Subjects continued stable doses of 
antidiabetes medication throughout the study. Insulin sensitivity was assessed 
by measuring the glucose disappearance rate (GDR) during the last 40 min of a 
5-h hyperinsulinemic, euglycemic clamp. Insulin secretion was determined as 
the acute insulin response to glucose (AIRg) during the first 10 min of a 
frequently sampled intravenous glucose tolerance test. Where noted, data were 
adjusted for baseline values and background antidiabetes medication. Results: 
An adjusted mean increase from baseline in GDR (last observation carried 
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forward), at Week 12, was observed with dapagliflozin (7.98%) versus a 
decrease with placebo (-9.99%). The 19.97% (95% confidence interval 5.75-
36.10) difference in GDR versus placebo was statistically significant 
(P=0.0059). A change from baseline in adjusted mean AIRg of 15.39 mU/L min 
was observed with dapagliflozin at Week 12, versus -12.73 mU/L min with 
placebo (P=0.0598). Over 12 weeks, numerical reductions from baseline in 
glycosylated hemoglobin (HbA1c), fasting plasma glucose, and body weight 
were observed with dapagliflozin (-0.38%, -0.39 mmol/L, and -1.58%, 
respectively) versus slight numerical increases with placebo (0.03%, 0.26 
mmol/L, and 0.62%, respectively). In patients with T2DM and inadequate 
glycemic control, dapagliflozin treatment improved insulin sensitivity in the 
setting of reductions in HbA1c and weight. 
39.Luke Norton96 et al.,Hyperglycemia plays an important role in the 
pathogenesis of type 2 diabetes mellitus, i.e., glucotoxicity, and it also is the 
major risk factor for microvascular complications. Thus, effective glycemic 
control will not only reduce the incidence of microvascular complications but 
also correct some of the metabolic abnormalities that contribute to the 
progression of the disease. Achieving durable tight glycemic control is 
challenging because of progressive β-cell failure and is hampered by increased 
frequency of side effects, e.g., hypoglycemia and weight gain. Most recently, 
inhibitors of the renal sodium-glucose cotransporter have been developed to 
produce glucosuria and reduce the plasma glucose concentration. These oral 
antidiabetic agents have the potential to improve glycemic control while 
avoiding hypoglycemia, to correct the glucotoxicity, and to promote weight 
loss.  
40.André J Scheen97 et al.,Empagliflozin is an orally active, potent and 
selective inhibitor of sodium glucose co-transporter 2 (SGLT2), currently in 
clinical development to improve glycaemic control in adults with type 2 
diabetes mellitus (T2DM). SGLT2 inhibitors, including empagliflozin, are the 
first pharmacological class of antidiabetes agents to target the kidney in order to 
remove excess glucose from the body and, thus, offer new options for T2DM 
management. SGLT2 inhibitors exert their effects independently of insulin. 
Following single and multiple oral doses (0.5-800 mg), empagliflozin was 
rapidly absorbed and reached peak plasma concentrations after approximately 
1.33-3.0 h, before showing a biphasic decline. The mean terminal half-life 
ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h 
in multiple-dose studies. Following multiple oral doses, increases in exposure 
were dose-proportional and trough concentrations remained constant after day 
6, indicating a steady state had been reached. Oral clearance at steady state was 
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similar to corresponding single-dose values, suggesting linear pharmacokinetics 
with respect to time. No clinically relevant alterations in pharmacokinetics were 
observed in mild to severe hepatic impairment, or in mild to severe renal 
impairment and end-stage renal disease. Clinical studies did not reveal any 
relevant drug-drug interactions with several other drugs commonly prescribed 
to patients with T2DM, including warfarin. Urinary glucose excretion (UGE) 
rates were higher with empagliflozin versus placebo and increased with dose, 
but no relevant impact on 24-h urine volume was observed. Increased UGE 
resulted in proportional reductions in fasting plasma glucose and mean daily 
glucose concentrations. 
41.Chiara Ghezzi98 et al.,SGLT2 inhibitors are a new class of drugs that have 
been recently developed to treat type II diabetes. They lower glucose levels by 
inhibiting the renal Na+/glucose cotransporter SGLT2, thereby increasing the 
amount of glucose excreted in the urine. Pharmacodynamics studies have raised 
questions about how these inhibitors reach SGLT2 in the brush border 
membrane of the S1 and S2 segments of the renal proximal tubule: are these 
drugs filtered by the glomerulus and act extracellularly, or do they enter the cell 
and act intracellularly?  Inhibition of SGLT2 activity (Na+/glucose currents) 
was determined using the whole-cell patch clamp that allows controlling the 
composition of both the extracellular and intracellular solutions. We compared 
the results to those obtained using the nonselective SGLT inhibitor phlorizin,  
Our results showed that SGLT2 transport (IC50 2 nmol/L)  ineffective from the 
intracellular compartment at both low (5 mmol/L) and high (150 mmol/L) 
intracellular NaCl concentrations. We conclude that SGLT2 from the 
extracellular side of the plasma membrane, suggesting that it is filtered from the 
blood through the glomerulus and acts from within the tubule lumen. 
42.André J99 et al., Inhibitors of sodium-glucose cotransporters type 2 
(SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and 
thereby increasing urinary glucose excretion. They are proposed as a novel 
approach for the management of type 2 diabetes mellitus. They have proven 
their efficacy in reducing glycated haemoglobin, without inducing 
hypoglycaemia, as monotherapy or in combination with various other glucose-
lowering agents, with the add-on value of promoting some weight loss and 
lowering arterial blood pressure. As they may be used concomitantly with many 
other drugs, we review the potential drug-drug interactions (DDIs) regarding the 
three leaders in the class (dapagliglozin, canagliflozin and empagliflozin). Most 
of the available studies were performed in healthy volunteers and have assessed 
the pharmacokinetic interferences with a single administration of the SGLT2 
inhibitor. The exposure [assessed by peak plasma concentrations (C max) and 
area under the concentration-time curve (AUC)] to each SGLT2 inhibitor tested 
was not significantly influenced by the concomitant administration of other 
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glucose-lowering agents or cardiovascular agents commonly used in patients 
with type 2 diabetes. Reciprocally, these medications did not influence the 
pharmacokinetic parameters of dapagliflozin, canagliflozin or empagliflozin. 
Some modest changes were not considered as clinically relevant. However, 
drugs that could specifically interfere with the metabolic pathways of SGLT2 
inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-
glucuronosyltransferase (UGT)] may result in significant changes in the 
exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin. 
Potential DDIs in patients with type 2 diabetes receiving chronic treatment with 
an SGLT2 inhibitor deserve further attention, especially in individuals treated 
with several medications or in more fragile patients with hepatic and/or renal 
impairment. 
43.David Polidori100 et al.,Canagliflozin, a sodium glucose cotransporter 2 
(SGLT2) inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the 
hypothesis that intestinal canagliflozin levels postdose are sufficiently high to 
transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose 
absorption.This two-period, crossover study evaluated effects of canagliflozin 
on intestinal glucose absorption in 20 healthy subjects using a dual-tracer 
method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal 
mixed-meal tolerance test. Plasma glucose, (3)H-glucose, (14)C-glucose, and 
insulin were measured frequently for 6 h to calculate rates of appearance of oral 
glucose (R(a)O) in plasma, endogenous glucose production, and glucose 
disposal. Compared with placebo, canagliflozin treatment reduced postprandial 
plasma glucose and insulin excursions (incremental 0- to 2-h area under the 
curve [AUC(0-2h)] reductions of 35% and 43%, respectively; P < 0.001 for 
both), increased 0- to 6-h urinary glucose excretion (UGE(0-6h), 18.2 ± 5.6 vs 
<0.2 g; P < 0.001), and delayed R(a)O. Canagliflozin reduced AUC R(a)O by 
31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% 
over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin 
increased R(a)O such that total AUC R(a)O over 0 to 6 h was <6% lower versus 
placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (∼10%) reduction in 
acetaminophen absorption was observed over the first 2 h, but this difference 
was not sufficient to explain the reduction in R(a)O. Total glucose disposal over 
0 to 6 h was similar across groups. Canagliflozin reduces postprandial plasma 
glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and 
delaying R(a)O, likely due to intestinal SGLT1 inhibition. 
44.Hideaki Jinnouchi101 et al.,We investigated the impact of reduced renal 
function on 24-h glucose variability in Japanese patients with type 2 diabetes 
mellitus (T2DM) treated with luseogliflozin. In this double-blind, placebo-
controlled, crossover study, 37 Japanese patients with T2DM [glycated 
hemoglobin (HbA1c) 7.0-10.0%] and estimated glomerular filtration rate 
REVIEW OF LITERATURE 
 
DEPARTMENT OF PHARMACY PRACTICE Page 110 
 
(eGFR) ≥45 mL/min/1.73 m(2) were randomized into two groups in which 
patients first received luseogliflozin then placebo, or vice versa, for 7 days each. 
Twenty-four-hour glucose variability was measured on day 7 in each period and 
was compared among patients divided into three groups according to their 
baseline eGFR (mL/min/1.73 m(2)): normal (≥90; n = 13; normal group), 
normal-to-mildly reduced renal function (≥75 to <90; n = 12; normal-mild 
group), and mild-to-moderately reduced renal function (<75; n = 9; mild-
moderate group). Results: The mean [95% confidence interval (CI)] placebo-
subtracted 24-h cumulative urinary glucose excretion (g) was 82.1 (72.7, 91.5), 
82.5 (73.4, 91.5), and 62.2 (51.2, 73.3); the placebo-subtracted 24-h mean 
glucose concentration (mg/dL) was -24.39 (-32.53, -16.26), -28.28 (-39.35, -
17.22), and -11.53 (-23.93, 0.86); and the placebo-subtracted peak postprandial 
glucose (mg/dL) was -26.9 (-46.9, -6.9), -38.1 (-59.6, -16.6), and 1.5 (-25.5, 
28.4) in the normal, normal-mild, and mild-moderate groups, respectively. The 
mean lowest glucose concentrations (placebo vs. luseogliflozin, mg/dL) 
decreased to similar levels in the normal (115.4 vs. 93.4), normal-mild (121.0 
vs. 97.9), and mild-moderate (104.0 vs. 91.1) groups. This post hoc subanalysis 
revealed that although mild-to-moderately reduced renal function attenuated the 
glucose-lowering effects of luseogliflozin on peak postprandial glucose, it did 
not attenuate the effects of luseogliflozin on fasting glucose. These findings 
may explain the smaller increase in urinary glucose excretion in these patients 
relative to patients with normal renal function or normal-to-moderately reduced 
renal function.  
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AIM OF THE STUDY: 
                      To observe the blood sugar lowering and other pleiotropic effects 
like changes in body weight and BMI, systolic and diastolic BP changes in type 
2 diabetes mellitus subjects with the latest anti diabetic agents of the  class 
SGLT2 inhibitors namely Canagliflozin, Dapagliflozin and Empagliflozin over 
a minimum period of 3 months. 
OBJECTIVES: 
 To assess the number of hypoglycaemic events. 
 To assess the effect on body weight. 
 To determine macrovascular complication in type 2 DM 
 To compare and assess effect of drugs on type 2 DM and the role in renal 
protection. 
SUBJECTS: 
                        It is decided to recruit 35 subjects of Type 2 DM, male and 
female, taking any one of the three SGLT2 inhibitors that are available in the 
indian pharmaceutical market namely canagliflozin, Dapagliflozin and 
Empagliflozin attending the outpatient services of the Madurai Institute of 
Diabetes and Endocrine (MIDE) practice and research at 89A,East veli street 
and 96,Nakkeerar street, Madurai. 
INCLUSION CRITERIA: 
                       Subjects should be suffering from Type 2 Diabetes Mellitus as 
per the usual clinical and laboratory criteria that is followed at MIDE. They 
should all be adults above the age 18 years. Even though it is only an 
observational study informed consent was obtained from all subjects. 
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                      Most of the patients were already on one or two insulin 
secretagogues and one or two insulin sensitizers. Somewhere on alpha 
glucosidase inhibitors. Subjects with cardiovascular risks were on appropriate 
anti platelet therapy and any one statin, hypertensives were on appropriate anti 
hypertensives. No dosage adjustments or alterations of these drugs were made 
during the 3 months study period. 
EXCLUSION CRITERIA: 
                     Drug naive patients who were not on adequate doses of insulin 
secretagogues or sensitizers, subjects who had moderate to severe renal failure, 
mild, moderate, severe liver disease and acute coronary syndrome, infarct, 
stroke or ketoacidosis or suffering from any acute or chronic infections. 
METHODOLOGY 
                     In this observational study we did not disturb the routine of the 
patients or the physicians in the clinic. We tried to collect atleast 10 subjects in 
each group with a total of 30 subjects in all. we recruited 35 subjects in all out 
of which 6 were excluded due to reasons of inadequate length of treatment. The 
parameters which we studied with a view to compare head to head the three 
agents are body weight, BMI, systolic and diastolic and 2 hours post prandial 
blood sugar values 
         Clinical evaluation regarding age, gender, duration of disease, age onset, 
any other complication and family history evaluation were done in all the cases. 
         Patient were received after the treatment measurement. The observed 
parameter were analysed. Discussion was held with Diabetologist for the 
interpretation of collected data. 
         The efficacy of each group was determined and conclusion was drawn. 
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        Finally patient were counselled regarding the importance of strict glycemic 
control attained by diabetic diet & regular exercise with proper drug treatment. 
COLLECTION AND COMPILATION OF DATA: 
Source of data used: 
Patient interview 
Patient case notes 
Treatment chart 
CALCULATION OF BODY MASS INDEX (BMI): 
             BMI can be calculated by measuring the height and weight of the 
person. 
BMI=Weight (kg)/height2 (cm2) 
            BMI of 10-18.5 shows underweight;18.5-23 shows normal;23-27.5 
shows over weight and greater than 27.5 shows obese. 
STATISTICAL ANALYSIS: 
STATISTICAL TOOLS: 
                The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of graph pad 
instat. Using this software mean, standard deviation, and P values were 
calculated. P value less than 0.05 is taken to denote significant relationship.  
               Statistical method used is the student T test for paired samples. 
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AN OBSERVATIONAL STUDY ON THE COMPARATIVE EFFICACY 
AND SAFETY OF CANAGLIIFLOZIN, DAPAGLIFLOZIN AND 
EMPAGLIFLOZIN IN TYPE 2 DM 
 
 
Table 1:AGE DISTRIBUTION 
DRUG 30-39 40-49 50-59 60-69 70-79 80-89 
CANAGLIFLOZIN 0 6 2 3 1 0 
DAPAGLIFLOZIN 1 1 2 3 1 1 
EMPAGLIFLOZIN 1 2 3 2 0 0 
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Table 2:SEX DISTRIBUTION 
 
SEX CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
MALE 6 5 2 
FEMALE 6 4 6 
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Table 3: RESIDENCE 
AREA CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
URBAN 8 7 6 
SEMI 
URABAN 
3 1 2 
RURAL 1 1 0 
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Table 4:BMI BEFORE AND AFTER THERPY 
 
CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
BEFORE AFTER BEFORE AFTER BEFORE AFTER 
30.3 27.1 27.1 25.3 30.8 27.6 
28 26.4 22.2 22.2 27.3 27.3 
22.5 20.4 27.8 26.1 26.7 24 
29 32 29.2 29.2 23.6 22.7 
30 27.9 23.7 23.7 30.4 28.9 
28.8 29.24 21.8 22.4 26.2 26.2 
28.9 27.8 20.9 20.9 30.2 25.1 
28.7 27.7 28.7 26.9 24.5 24.5 
29.1 27.4 29 26.7   
30.4 27.8     
30.9 27.9     
21.6 21     
 
 
       
           CANAGLIFLOZIN                                     DAPAGLIFLOZIN                                EMPAGLIFLOZIN 
 
BEFORE                 AFTER                    BEFORE                      AFTER                    BEFORE                     AFTER 
40__                            __ 40                   40 __                                __40                40__                               __40 
35__                            __35                    35 __                                __   35             35__                               __35 
30__                            __30                    30 __                                __30                30__                               __30 
25__                            __25                     25__    __25                25__                              __25 
20__                            __  20                   20__                                __20                 20__                              __20 
15__                             __15                    15 __                                __15                15__                               _ 15 
10__                             __10                   10                                           10                10                                      10                                
 5                                         5                     5                                              5                 5                                          5 
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MEAN 28.18 26.88 25.6 24.82 27.46 25.78 
SD 2.99 3.20 3.408 2.698 2.755 2.080 
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Table 5:BODY WEIGHT BEFORE AND AFTER THERAPY 
 
CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
BEFORE AFTER BEFORE AFTER BEFORE AFTER 
96 86 73 68 85 76 
70 66 60 62 61 61 
54 49 65 61 70 63 
67 74 63 63 49 47 
80 74 68 68 63 60 
72 73 56 58 82 82 
75 72 49 49 71 59 
57 55 81 76 72 72 
85 80 68 62.4   
93 85     
82 74     
67 65   
 
 
 
 
 
          CANAGLIFLOZIN                                     DAPAGLIFLOZIN                                EMPAGLIFLOZIN 
 
BEFORE                 AFTER                    BEFORE                      AFTER                    BEFORE                     AFTER 
90__                            __ 90                   90 __                                __90                90 __                              __90 
80__                            __80                    80 __                                __  80              80 __                              __80 
70__                            __70                    70 __                                __70                70__                               __70 
60__                            __60                   60 __    __60                60__                              __60 
50__                            __ 50                   50 __                                 __50               50__                               __50 
40__                             __40                    40 __                                __40                40__                              __40 
30__                             __30                   30                                           30                30                                      30                                
20                                       20                    20                                           20              20                                      20          
  10                                      10                 10                                             10             10                                       10           
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MEAN 74.83 71.08 64.77 63.04 69.12 65 
SD 13.02 11.01 9.37 7.46 11.58 11.10 
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Table 6:SYSTOLIC BP CHANGES BEFORE AND AFTER THERAPY 
 
CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
BEFORE 
mm/hg 
AFTER 
mm/hg 
BEFORE 
mm/hg 
AFTER 
mm/hg 
BEFORE 
mm/hg 
AFTER 
mm/hg 
122 131 165 156 165 134 
180 142 145 133 128 128 
147 126 125 122 164 142 
153 143 206 192 149 135 
140 125 131 123 160 154 
114 120 128 112 153 147 
156 140 117 144 158 150 
110 118 150 125 165 130 
120 111 130 103   
165 145     
120 120     
128 130     
 
 
 
           CANAGLIFLOZIN                                     DAPAGLIFLOZIN                                EMPAGLIFLOZIN 
 
BEFORE                 AFTER                    BEFORE                      AFTER                    BEFORE                     AFTER 
180__                              __ 180          180 __                                 __180          180 __                                 180     
170__                              __170           170  __                                __ 170         170 __                                 170  
160__                              __160            160__                                  __160          160__                                 160 
150__                              __150            150 __     __150           150__                                150 
140__                               __ 140          140 __                                 __140           140__                                140 
130__                               __130            130__                                 __130           130__                                130 
120__                               __120           120                                             120         120                                    120                              
110                                         110            110                                         110           110                                    110           
100                                          100         100                                            100          100                                    100              
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MEAN 137.91 129.25 144.11 134.44 155.25 140 
SD 22.34 11.19 27.46 26.78 12.44 9.66 
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144,11 134,44 
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22,34 11,9 
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B A B A B A
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Table 7:DIASTOLIC BP CHANGES BEFORE AND AFTER THERAPY 
 
CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
BEFORE 
mm/hg 
AFTER 
mm/hg 
BEFORE 
mm/hg 
AFTER 
mm/hg 
BEFORE 
mm/hg 
AFTER 
mm/hg 
65 76 72 74 98 84 
98 73 72 72 79 79 
7+ 67 70 70 103 85 
84 72 86 83 87 80 
70 79 85 75 86 100 
71 73 85 73 80 76 
108 90 69 80 98 90 
70 80 77 67 90 86 
78 70 90 74   
87 78     
84 70     
71 75     
 
 
 
          CANAGLIFLOZIN                                     DAPAGLIFLOZIN                                EMPAGLIFLOZIN 
 
BEFORE                 AFTER                    BEFORE                      AFTER                    BEFORE                     AFTER 
100__                              __ 100          100 __                                 __100          100 __                                 100     
90  __                               __90              90  __                                 __ 90              90__                                 90  
80  __                               __80              80__                                   __80               80__                                 80 
70  __                               __70              70 __     __70               70__                                 70 
60  __                               __ 60             60 __                                   __60              60__                                  60 
50  __                                __50             50  __                                  __50              50__                                  50 
40  __                                __40             40                                             40               40                                      40                              
30                                            30            30                                             30              30                                       30           
20                                            20            20                                         __20             20                                        20              
 10                                            10            10                                            10               10                                      10                      
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MEAN 80.16 76.08 78.44 74.22 90.12 85 
SD 12.77 6.41 8.079 4.841 8.806 7.502 
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Table 8:POST PRANDIAL BLOOD SUGAR VALUE BEFORE AND AFTER 
THERAPY 
 
CANAGLIFLOZIN DAPAGLIFLOZIN EMPAGLIFLOZIN 
BEFORE 
mg/dl 
AFTER 
mg/dl 
BEFORE 
mg/dl 
AFTER 
mg/dl 
BEFORE 
mg/dl 
AFTER 
mg/dl 
385 209 306 160 448 135 
332 136 291 198 437 277 
360 146 282 143 336 124 
285 176 248 177 304 125 
370 271 154 173 324 270 
281 126 216 155 191 140 
337 390 389 175 165 179 
500 128 255 174 380 157 
232 200 374 436   
140 140     
424 176     
318 168     
 
 
           CANAGLIFLOZIN                                     DAPAGLIFLOZIN                                EMPAGLIFLOZIN 
 
BEFORE                 AFTER                     BEFORE                          AFTER                    BEFORE                   AFTER 
500__                              __ 500          500 __                                 __500          500 __                                 500     
450__                              __450            450__                                 __ 450          450__                                 450  
400 __                             __400            400__                                  __400           400__                                400 
350__                               __350           350__     __350           350__                                350 
300__                               __ 300          300__                                  __300           300__                                300    
250 __                              __250           250__                                  __250           250__                                250 
200 __                              __200           200                                             200          200                                   200                                
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MEAN 330.33 188.83 279.44 199 348.12 188.37 
SD 92.23 75.78 73.43 90.22 81.53 54.98 
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RESULTS 
                     In all 35 subjects were recruited and six were eliminated because 
of inadequate drug exposure period. Final study subjects number remained at 29 
subjects;12 subjects were on canagliflozin,9 on dapagliflozin and 8 on 
Empagliflozin. 
AGE DISTRIBUTION OF THE SUBJECTS: 
                    The mean age of the subjects on canagliflozin is 
54.33 ± 9.93years:of the subjects on dapagliflozin 59.77 ± 15.23 and an 
empagliflozin 50.88±9.92years.The age distribution of the three groups are not 
statistically significantly different (cana vs dapa p=0.37),(cana vs empa 
p=0.46),(dapa vs empa p=0.17). 
SEX DISTRIBUTION: 
                     The sex distribution in the canagliflozin group are M:F=6:6 ; in the 
dapagliflozin group are M:F=5:4 ; and in the Empagliflozin group are 
M:F=2:6.The sex distribution in the three groups are not uniform for the simple 
reason, subjects are recruited on a first come basis. This also explains the 
different number of subjects on canagliflozin, dapagliflozin and Empagliflozin. 
RESIDENCE: 
                   The study subjects are drawn from around Madurai city and the city 
proper. The distribution of subjects between urban, rural and semi urban 
residences were not uniform between the three groups. In the Cangliflozin 
group 8 subjects were from urban localities,3 from semi urban and 1 from rural 
locality. 
                  In the dapagliflozin group 7 subjects were from the urban locality,1 
each from semi urban and rural localities. 
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                  In the Empagliflozin group 6 subjects were from urban localities and 
2 from semi urban localities.     
BMI: 
                     In the canagliflozin group the BMI value before therapy are 
28.18±2.99(M±SD) and after therapy 26.9±3.2.Though it is not statistically 
significantly different (P=0.32) there is a reduction of 1.28 points in BMI after 
therapy with canagliflozin. 
                 In the dapagliflozin group the BMI value before therapy is 25.6±3.41 
and after therapy is 24.8± 2.69.Though these values were not statistically 
significantly different there is fall of 0.78 points in BMI after therapy with 
Dapagliflozin.(P=0.19) 
                  In the Empagliflozin group the BMI before therapy is 27.46±2.76 
and after therapy is 25.79± 2.08.Though these values are not statistically 
significantly different (P=0.6) there is observed a fall of 1.67 points in the BMI 
after therapy. 
              In the Canagliflozin group two subjects showed an increase in BMI 
after therapy. 
              In the Dapagliflozin group three subjects did not show any change in 
BMI and one subjects actually showed increase in BMI. 
              In the Empagliflozin group three subjects did not show any change in 
BMI. 
              The before treatment BMI of the three samples were not statistically 
significantly different. 
RESULTS 
 
DEPARTMENT OF PHARMACY PRACTICE Page 129 
 
                The after treatment fall in the mean BMI is marked in the 
Empagliflozin group (1.67 points),moderate in the Canagliflozin group (1.28 
points) and least with the Dapagliflozin group (0.78 points). 
BODY WEIGHT: 
                  The body weight of Canagliflozin group before therapy is 
74.8±13.02 kgs and after therapy was 71.08±11.01 kgs.The fall in body weight 
of 3.75kgs was not statistically significant (P=0.51).Two subjects had gained 
7kg and 1kg respectively. 
                  The body weight in the  Dapagliflozin group in 64.7±9.38 kgs 
before therapy and 63.04±7.46 kgs after therapy.The mean fall of 1.66 kgs after 
therapy.Three subjects in this group did not shows any changes in body weight 
after therapy.Two subjects gained 2kgs each with therapy in this group. 
                   The body weight in the Empagliflozin group before therapy is 
69.13±11.58kgs and after therapy 65±11.11kgs.This mean loss of 4.02kgs in 
this group was not statistically significant (P=0.76).Three subjects in this group 
did not loose any weight after therapy. 
                  The mean weight between there these samples before therapy is not 
significantly different. 
SYSTOLIC BP: 
                     The systolic blood pressure in the canagliflozin group before 
therapy is 137.9±22.3 mmhg and after therapy is 129.3±11.2 mmhg.This fall of 
8.6 mmhg with therapy was not statistically significantly less (P=0.25).Four 
subjects in this group had a rise of 9,6,8 and 2mmhg with therapy. One subject 
systolic BP did not change with therapy. 
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                    In the Dapagliflozin the systolic BP before therapy is 144.1±27.46 
mmhg and after therapy 134.4±26.8 mmhg.This fall of a mean 9.7 mmhg is 
statistically low (P=0.02).Only one subjects in the group had a risk of 27mmhg 
systolic BP after therapy. 
                    In the Empagliflozin group the systolic BP before therapy is 
155.3±12.4 mmhg and after therapy 140±9.7mmhg.This fall of 14.4mmhg is 
not statistically significantly low. Only one subjects in this group did not show 
any changes in the systolic BP. 
                     The systolic BP in the Empagliflozin group was statistically 
different before the start of therapy. It was high compared to Canagliflozin 
(P=0.04) and Dapagliflozin (P=0.0001) groups. The statistical difference is 
maintained only between Canagliflozin and Empagliflozin group after therapy. 
DIASTOLIC BP: 
                    The diastolic BP in the Canagliflozin before therapy is 
80.2±12.8mmhg and after therapy 76.1±6.4mmhg. This 4.1 mmhg fall in 
diastolic pressure in this group is statistically significant had a risc of diastolic 
BP after therapy at 11,9,2 and 10mmhg respectively. 
                   The diastolic BP in the Dapagliflozin group before therapy is 
78.4±8.1mmhg and after therapy 74.2±4.8mmhg.This 4.2 mmhg mean fall of 
diastolic BP was not significantly low (P=0.23).Two subjects in this group 
showed 2 and 11 mmhg elevation of diastolic BP and two other subjects should 
no change in their diastolic BP after therapy. 
                     In the Empagliflozin group the diastolic BP before therapy is 
90.1±8.8mmhg and after therapy 85±7.5mmhg.This 5.1 mmhg fall of diastolic 
pressure is not statistically low (P=0.2).One subject in this group did not show 
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any change in the diastolic BP after therapy and one subject showed  a risc of  
14mmhg after therapy. 
                    Before the start of therapy Empagliflozin group had a statistically 
high blood pressure compared to the Dapagliflozin group(P=0.01) and 
Canagliflozin group (P=0.05).That statistical difference was maintained post 
therapy with Dapagliflozin group (P=0.01) and Empagliflozin group (P=0.02). 
2 Hours post prandial blood sugar: 
                 Two hour post prandial sugar value in the Canagliflozin group before 
therapy are 330.3±92.2mgm/dl and after therapy 188.8±75.8 mgm/dl.This fall 
of 141.5mgm/dl of blood sugar is statistically highly significant (P<0.001).Only 
one subject in this group had a 53 mgm/dl risc in post prandial blood sugar 
value and one other subjects did not shows any difference in the 2 hour post 
prandial blood sugar. 
               Two  hour post prandial blood sugar value in the Dapagliflozin group 
before therapy is 279.4±73±4 mgm/dl and after therapy 199±90.2 mgm/dl.This 
mean fall of 80.4 mgm/dl of 2 hour post prandial blood sugar value is 
statistically significantly low (P=0.05).Only one subject in this group had a risc 
of 62mgm/dl of 2 hour post prandial blood sugar value after therapy. 
                    Two hour post prandial blood sugar values before therapy in the 
Empagliflozin group is 348.1 ± 188.4 mgm/dl and after therapy 
188.4±55mgm/dl.This 159.7mgm/dl fall in ppbs of this group is statistically 
highly significant (P<0.001).No subject in this group showed an elevation of 
blood sugar values after therapy. 
                      The 2 hours post prandial blood pressure values in all the three 
groups before therapy are not statistically different. 
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DISCUSSION 
                             SGLT2 inhibitors are a new class of anti diabetics which act 
independently of insulin secretion and insulin sensitization. They address a 
compensatory renal mechanism and help diabetic subjects achieve better 
diabetic control. They block the renal tubular glucose reabsorbtion mechanisms 
involving the SGLT mechanism. In every diabetic as a compensatory 
mechanism the system gets induced and almost completely reabsorbs the excess 
glucose that is filtered by the glomerulus. The only apprehension when such a 
manipulation was contemplated is the interference with glucose absorption 
elsewhere like in the gut and the consequence of excess glucose in the urine that 
comes in constant with the genito urinary tracts of men and women. Such 
apprehensions are dispelled by the highly selective nature of the present 
derivatives of  phlorizin which act almost exclusively on the SGLT2 paths. In 
real life UTI and genital infections are not very common with SGLT2 inhibitors 
usage as they drastically reduce the tissue  glucose levels which also contribute 
to such fungal infections. 
                        The loss of approximately 70gms of glucose in subjects taking 
SGLT2 inhibitors, which amounts to some degree of starvation and excess 
excretion of water and sodium with the forced glycosuria were expected to 
result  in at least symptomatic side effects. Unlike the presence of sugar in the 
urine which is unequivocally harmful to the patients, polyurea, water and salt 
depletion and some degree of starvation had both positive and negative results. 
Some patients do complains of polyurea and polydipsia. Many have postual 
hypotension and reduction in systolic and diastolic blood pressure. Some of the 
cardiovascular benefits which were demonstrated in Empa -Reg trial utilizing 
Empagliflozin might be the result of partial starvation. 
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                     With the availability of three agents in the same class of drugs, 
commercial interests more than scientific benefits prevail. In our small, pilot, 
observational study we have weakly attempted to have a head to head 
comparision between the three commercially available agents. 
                     For such an observation study we have selected a well attended 
diabetic clinic situated in the  heart of Madurai city to collect patients. 
                     Results revealed than the 2 hour post prandial blood sugar value 
showed a significant fall in all the three group of patients. 
                  (Canagliflozin=141.5,Dapagliflozin=80.4,Empaliflozin=159.7).Thus 
in their hypoglycemic effect Empagliflozin seems the best. 
                       The changes in the BP post therapy are  
(Canagliflozin=8.6/4.1mmhg,Dapagliflozin=9.7/4.2mmhg,Empagliflozin=14.4/
5.1mmhg). Though only the systolic BP values in the Dapagliflozin group 
reached statistical significance, BP responses could be called equal. The greater 
fall in the Empagliflozin group is probably due to the higher levels that 
prevailed before therapy. 
                      The fall in the body weight 
are(Canagliflozin=3.75kgs,Dapagliflozin=1.66kgsandEmpagliflozin=4.02kgs).T
hough none of the groups reached significance, the weight loss is observable. 
The changes in the BMI points are (Canagliflozin=1.28,Dapagliflozin=0.78, and 
Empagliflozin=1.67) 
Thus the best results are observable with Empagliflozin on the blood sugar, 
blood pressure and body weight parameters. 
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CONCLUSION 
                       This study has limitations because of the small number, being 
only observational and pilot study. Only the age group of the subjects and body 
weight were in the same range in the three groups. However the following 
conclusions can be made from the observed data. 
                    1.Body weight and BMI fell in all the three groups with 
Canagliflozin 100mg/day, Dapagliflozin 10mg/day, and Empagliflozin 
25mg/day. The best fall has observed with Empagliflozin 
                    2.Fall in the systolic and diastolic blood pressure did not reach 
significance in all the three groups. The Empagliflozin group which had high 
levels to start with should greater fall. 
                    3.The blood sugar reductions at 2 hour post prandial blood sugar 
value were statistically significance in all the three groups. The higher 
reductions are seen with the Empagliflozin group. 
                    4.Thus it can be considered that Empagliflozin among the 3 
available SGLT2 inhibitor at maximum permitted doses appears slightly more 
efficacious however the differences were not statistically efficient. 
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CASE RECORD FORM 
1.Personal details: 
Name of the patient: ..........................   Date: ............. 
MR Number .....................    Age .............. Sex: Male/Female 
Occupation: 
Address:  ....................................................................................... 
                  ....................................................................................... 
                  ....................................................................................... 
2.Medical history: 
Type 2 DM                               : Yes/No                           Duration of DM                 : 
HTN                                          : Yes/No                           Duration of HTN               : 
Family history of DM               : Yes/No                           Family history of HTN      :Yes/No 
Smoking                                    : Yes/No                           Alcoholic                           :Yes/No 
3.Laboratory investigation: 
Parameters Baseline Visit 1 
(8 week) 
Visit 2 
(16 week) 
     Microalbuminuria 
   
       Blood pressure 
   
 
FMD 
Before  
inflating 
Systole 
   
Diastole 
   
After 
inflating 
Systole 
   
Diastole 
   
 
4.Treatment: 
Therapy Drug Name Duration 
 
Study drug 
 
  
 
Oral hypoglycemic 
 
  
 
Anti hypertensive drug 
 
  
 
Others 
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5.Side effects: 
 
6.Any other details: .................................................................................... 
                                 .................................................................................... 
 
 
Doctor's signature: ....................... 
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